WO2004092161A1 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease - Google Patents

Inhibitors of serine proteases, particularly hcv ns3-ns4a protease Download PDF

Info

Publication number
WO2004092161A1
WO2004092161A1 PCT/US2004/011011 US2004011011W WO2004092161A1 WO 2004092161 A1 WO2004092161 A1 WO 2004092161A1 US 2004011011 W US2004011011 W US 2004011011W WO 2004092161 A1 WO2004092161 A1 WO 2004092161A1
Authority
WO
WIPO (PCT)
Prior art keywords
aliphatic
independently
optionally
compound according
ring
Prior art date
Application number
PCT/US2004/011011
Other languages
French (fr)
Inventor
Kevin M. Cottrell
John Maxwell
Robert B. Perni
Janos Pitlik
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/412,600 external-priority patent/US7273885B2/en
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to EP04759361A priority Critical patent/EP1613620A1/en
Publication of WO2004092161A1 publication Critical patent/WO2004092161A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

  • the present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents .
  • the invention further relates to pharmaceutical compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection.
  • the invention also relates to processes for preparing the compounds and methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
  • HCV hepatitis C virus
  • the HCV genome encodes a polyprotein of 3010- 3033 amino acids [Q.L. Choo, et. al . , "Genetic Organization and Diversity of the Hepatitis C Virus.” Proc. Natl. Acad. Sci. USA, 88, pp. 2451-2455 (1991); N. Kato et al . , "Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis," Proc. Natl. Acad. Sci. USA, 87, pp. 9524-9528 (1990); A. Takamizawa et. al . , "Structure and
  • the HCV nonstructural (NS) proteins are presumed to provide the essential catalytic machinery for viral replication.
  • the NS proteins are derived by proteolytic cleavage of the polyprotein [R. * Bartenschlager et. al . , "Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions," J. Virol., 67, pp. 3835-3844 (1993); A. Grakoui et. al .
  • the HCV NS protein 3 contains a serine protease activity that helps process the majority of the viral enzymes, and is thus considered essential for viral replication and infectivity. It is known that mutations in the yellow fever virus NS3 protease decrease viral infectivity [Chambers, T.J. et. al . , "Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein", Proc. Natl. Acad. Sci. USA, 87, pp. 8898-8902 (1990)].
  • the first 181 amino acids of NS3 (residues 1027-1207 of the viral polyprotein) have been shown to contain the serine protease domain of NS3 that processes all four downstream sites of the HCV polyprotein [C. Lin et al . , "Hepatitis C Virus NS3 Serine Proteinase: Trans-Cleavage
  • HCV NS3 serine protease and its associated cofactor, NS4A helps process all of the viral enzymes, and is thus considered essential for viral replication. This processing appears to be analogous to that carried out by the human immunodeficiency virus aspartyl protease, which is also involved in viral enzyme processing. HIV protease inhibitors, which inhibit viral protein processing, are potent antiviral agents in man, indicating that interrupting this stage of the viral life cycle results in therapeutically active agents . Consequently HCV NS3 serine protease is also an attractive target for drug discovery. [0008] Several potential HCV protease inhibitors have been described [PCT publication Nos.
  • inhibitors would have therapeutic potential as protease inhibitors, particularly as serine protease inhibitors, and more particularly as HCV NS3 protease inhibitors.
  • such compounds may be useful as antiviral agents, particularly as anti-HCV agents .
  • the present invention provides a compound of formula I :
  • R 9 and Rg ⁇ are each independently: hydrogen- , (C1-C12 ) -aliphatic- ,
  • each of Ri and R 3 is independently and optionally substituted with up to 3 substituents independently selected from J; R, R 4 , and R are each independently: hydrogen- ,
  • R5 is each independently hydrogen or (C1-C12)- aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R5 is optionally substituted with sulfhydryl or hydroxy; or R 5 is Ph or -CH 2 Ph and R 5 ⁇ is H, wherein said P or -CH 2 Ph group is optionally substituted with up to 3 substituents independently selected from J; or R 5 and R 5 . together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, 0, SO, and S0 2 ; wherein said ring is optionally substituted with up to 2 substituents selected independently from J; W is :
  • m is 0 or 1; wherein each Re is independently: hydrogen- , (C1-C12) -aliphatic-, (C6-C10)-aryl-,
  • Ri3 is -C(0)R', -P(0)(OR') 2 , -S0 3 R', -R', or R 19 ;
  • R19 is : hydrogen, ⁇
  • R 19 0, NR19, S, SO, or S0 2 in a chemically stable arrangement; wherein up to 3 aliphatic carbon atoms in each R 19 are optionally replaced with -C(0)-; : wherein R ⁇ 9 is optionally substituted with up to 3 J substituents ; wherein any NR 19 , taken together with the nitrogen and a carbon adjacent to the nitrogen, optionally forms a 5- to 7-membered ring system, wherein said ring system optionally contains up to three additional heteroatoms selected from 0, N, NH, S, SO, and S0 2 in a chemically stable arrangement; R 14 and R 15 are independently halogen, -OR', -0C (O)N(R' ) 2 ,
  • Ris and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the Ris and Ris- atoms bound to the carbon atom are independently 0 or N; wherein said ring optionally contains up to 1 '.
  • the invention also relates to processes for preparing the above compounds and to compositions that comprise the above compounds and the use thereof.
  • Such compositions may be used to pre-treat invasive devices to be inserted into a patient, to treat biological samples, such as blood, prior to administration to a patient, and for direct administration to a patient.
  • the composition will be used to inhibit HCV replication and to lessen the risk of or the severity of HCV infection.
  • R 9 and Rg are each independently: hydrogen- ,
  • R 9 and Rio are optionally taken together with the ring atoms to which they are bound to form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system up to 3 heteroatoms independently selected from N, NH, 0, S, SO, or S0 2 ; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; or
  • Rio and Rn are optionally taken together with the ring atoms to which they are bound to form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, or S0 2 ; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
  • R 9 and Rii are optionally taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic or heterocyclic ring system containing up to 10 atoms; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; wherein each heteroatom in the heterocyclic ring system is selected from the group consisting of N, NH, 0, S, SO, or S0 2 ; Ri and R 3 are each independently: (C1-C12 ) -aliphatic-,
  • R 5 are each independently hydrogen or (C1-C12)- aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R 5 is optionally substituted with sulfhydryl or hydroxy; or R 5 is Ph or -CH 2 Ph and Rs- is H, wherein said Ph or -CH 2 Ph group is optionally substituted with up to 3 substituents independently selected from J; or
  • R 5 and R5. together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, 0, SO, and S0 2 ; wherein said ring is optionally substituted with up to 2 substituents selected independently from J;
  • m is 0 or 1; wherein each Re is independently: hydrogen-, (C1-C12) -aliphatic-, (C6-Cl0)-aryl-,
  • V is -C(0)-, -C(S)-,! -S(O)-, or -S(0) 2 -;
  • A is hydrogen or -C (R i2 ) (R ⁇ 2 ⁇ ) -T-R1 3 ;
  • T is oxygen or a bond
  • R 1 2 and R 1 2 ' are each independently: hydrogen- , or (C1-C6 ) -aliphatic- ; wherein up to two aliphatic carbon atoms in each of R 1 2 and Ri2 ⁇ are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, and S0 in a chemically stable arrangement; or
  • R 13 is -C(0)R', -P(0)(OR') 2 , -S0 3 R', -R', or -R 19 ;
  • R 19 is: hydrogen
  • Rig are optionally replaced by a heteroatom selected from 0, NRig, S, SO, or S0 in a chemically stable arrangement ; wherein up to 3 aliphatic carbon atoms in each R i9 are optionally replaced with -C(0)-; wherein R i9 is optionally substituted with up to 3 J substituents ; wherein any NR 19 , taken together with the nitrogen and a carbon adjacent to the nitrogen, optionally forms a 5- to 7-membered ring system, wherein said ring system optionally contains up to three additional heteroatoms selected from 0, N, NH, S, SO, and S0 2 in a chemically stable arrangement; Ri4 and R 5 are independently halogen, -OR'
  • Ris and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the R ⁇ 8 and Ris- atoms bound to the carbon atom are independently 0 or N; wherein ; said ring optionally contains up to 1 additional heteroatom selected from N, NH, 0, S, SO, and S0 2 ; wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, and a (C3-CIO) heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; provided that when R ⁇ 8 and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially
  • aryl as used herein means a monocyclic or bicyclic carbocyclic aromatic ring system. Phenyl is an example of a monocyclic aromatic ring system. Bicyclic aromatic ring systems include systems wherein both rings are aromatic, e.g., naphthyl, and systems wherein only one of the two rings is aromatic, e.g., tetralin. It is understood that as used herein, the term “ (C6-C10) -aryl-" includes any one of a C6, C7, C8, C9, and CIO monocyclic or bicyclic carbocyclic aromatic ring.
  • heterocyclyl as used herein means a monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from 0, N, NH, S, SO, and S0 2 in a chemically stable arrangement.
  • heterocyclyl one or both rings may contain said heteroatom or heteroatom groups.
  • (C5-C10)- heterocyclyl- includes any one of a C5, C6, C7, C8, C9, and CIO monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from 0, N, NH, and S in a chemically stable arrangement .
  • heteroaryl as used herein means a monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from 0, N, NH, and S in a chemically stable arrangement.
  • heteroaryl a monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from 0, N, NH, and S in a chemically stable arrangement.
  • - one or both rings may be aromatic;
  • (C5-C10) -heteroaryl- includes any one of a C5, C6, C7, C8, C9, and CIO monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from 0, N, NH, and S in a ; chemically stable arrangement.
  • aliphatic as used herein means a straight chained or branched alkyl, alkenyl or alkynyl. It is understood that as used herein, the term “(C1-C12)- aliphatic-” includes any one of a Cl, C2 , C3 , C4, C5, C6, C7, C8, C9, CIO, Cll, and C12 straight or branched alkyl chain of carbon atoms. It is also understood that alkenyl or alkynyl embodiments need at least two carbon atoms in the aliphatic chain.
  • cycloalkyl or cycloalkenyl refers to a monocyclic or fused or bridged bicyclic carbocyclic ring system that is not aromatic. Cycloalkenyl rings have one or more units of unsaturation. It is also understood that as used herein, the term “ (C3-C10) -cycloalkyl- or -cycloalkenyl-” includes any one of a C3 , C4, C5, C6, C7, C8, C9, and CIO monocyclic or fused or bridged bicyclic carbocyclic ring.
  • Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, nornbornyl, adamantyl and decalin-yl .
  • chemically stable arrangement refers to a compound structure that renders the compound sufficiently stable to allow manufacture and administration to a mammal by methods known in the art. Typically, such compounds are stable at a temperature of 40°C or less, in the absence of moisture or other chemically reactive condition, for at least a week.
  • V is -C(O)-.
  • the present invention provides a compound; of formula IA:
  • Ri, R 2 , R 3 , R 4 , R5 s' / R7; R9/ R9 ' Rio/ Rio- f Rii Rii' 1 i4 R i5/ i6; i8 i8 ' A, U, and W are as defined in any of the embodiments herein.
  • A is -C(R ⁇ 2 ) (R12 -T-R13;
  • R 12 and R 12' are both hydrogen
  • T is oxygen
  • R 1 3 is -C(0)R', -P(0) (OR') 2 , -SO3R', or -R';
  • R 14 and R 15 are both -R* ;
  • Ris- 0 and R i8 is absent;
  • Ri6 is R', wherein R' is selected from: (C1-C12 ) -aliphatic- , (C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12) - aliphatic-; wherein up to 5 atoms in R 1 are optionally and independently substituted with J. [0022] According to another embodiment of compounds of formula I,
  • Ri 3 is -C(0)R', -P(0)(OR') 2 , or -R';
  • Ri 4 and R i5 are both -R 1 and R' is (C1-C12) -aliphatic-; and Ri 6 is R' , wherein R' is (C1-C12 ) -aliphatic- .
  • the present invention provides a compound of formula IB:
  • R ' , Ri , R 2 , R 3 , R 4 b , R ' i ⁇ 7 ; R9 R9 ' f lO , RlO ' Rll / Rii ' , R13, and W are as defined in any of the embodiments herein.
  • R ⁇ 6 is -R' wherein R' is preferably methyl; R i4 and R 1 5 are both -R' and R' is preferably methyl; R 1 3 is -C(0)R' or -P(O) (0R') 2 , wherein R' is as defined in any of the embodiments herein; and Ri, R 2 , R3, R 4 , R5, Rs-, R 7 , Rg, R , Rio, Rio Rii Rii-/ and W are as defined in any of the embodiments herein. [0025] According to another embodiment of compounds of formula I,
  • A is -C(R 12 ) (Ri 2 -)-T-R ⁇ 3 ;
  • R12 is hydrogen and R ⁇ 2 - is (C1-C6) -aliphatic-; wherein up to two aliphatic carbon atoms in R i2' are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, and SO in a chemically stable arrangement;
  • T is oxygen;
  • Ri 6 is R', wherein R' is selected from: (C1-C12 ) -aliphatic- ,
  • R 12' is (C1-C6) -aliphatic-;
  • R 13 is -C(0)R', -P(0)(OR') 2 , or -R' ;
  • Ri 4 and R ⁇ 5 are both -R ' and R ' is (C1-C12 ) -aliphatic- ;
  • Ri6 is R ' , wherein R ' is (C1-C12 ) -aliphatic- .
  • the present invention provides a compound of formula IC :
  • R ⁇ Ri, R 2 , R 3 , R , Rs, Rs-, R7, Rg, Rg-, Rio, Ric, R11, Rii ' , R12 ' , R13, and W are as defined in any of the embodiments herein.
  • Ri ⁇ is -R 1 wherein R' is preferably methyl; R i4 and R 15 are both -R' and R' is preferably methyl; R 13 is -C(0)R' or -P(O) (OR') 2, wherein R' is as defined in any of the embodiments herein; R i2' is methyl and R 1# R 2 , R 3 , R 4 , R 5 , R 5' , R 7 , R 9 , Rg-, Rio, Rio ' , R11, Rii-, and W are as defined in any of the embodiments herein.
  • A is -C(R ⁇ 2 ) (R12 -T-R13;
  • T is oxygen or a bond
  • R13 is -Rig
  • R 14 and R 15 are both -R ' ;
  • Ris- 0 and R i8 is absent ;
  • Ri6 is R', wherein R' is selected from:
  • R' , Ri, R 2 , R3, R 4 , R5, Rs-, R7, R9, Rg ' , Rio, Rio-, R ⁇ , Rii ' , R12 ' , Rig, T, and W are as defined in any of the embodiments herein.
  • R x , R 2 , R3, R4, R5, R5 ' , R7, Rg, R9 ' , Rio, Ric, R11, Rii ' , and W are as defined in any of the embodiments herein;
  • T is a bond
  • Ri6 is -R' wherein R' is preferably methyl; R 14 and R 15 are both -R 1 and R' is preferably methyl; R 1 3 is Rig, wherein R 9 is as defined in any of the embodiments herein.
  • Rig is:
  • (C1-C12) -aliphatic- wherein 1 to 2 aliphatic carbon atoms in each Rig are optionally replaced by a heteroatom selected from 0 or NR 19 , in a chemically stable arrangement; wherein 1 to 2 aliphatic carbon atoms in each R 1 9 is optionally replaced with -C(0)-; wherein R 1 9 is optionally substituted with up to 3 J substituents .
  • R19 is: (C3-C6) -aliphatic-, wherein 1 to 2 aliphatic carbon atoms in each Ri are optionally replaced by a heteroatom selected from 0 or NRig, in a chemically stable arrangement; wherein 1 to 2 aliphatic carbon atoms in each Rig is optionally replaced with -C(O)-; wherein R ⁇ 9 is optionally substituted with up to 3 J substituents .
  • R19 is: (C3-C6) -aliphatic-, wherein 1 to 2 aliphatic carbon atoms in each Ri are optionally replaced by a heteroatom selected from 0 or NRig, in a chemically stable arrangement; wherein 1 to 2 aliphatic carbon atoms in each Rig is optionally replaced with -C(O)-; wherein R ⁇ 9 is optionally substituted with up to 3 J substituents .
  • Ris- CH 2 , and R ⁇ 8 is absent; U is oxygen; ?
  • Rie is R', -C(0)R ⁇ -P(0)(OR') 2 , or -S0 3 R' ; Ri 4 and Ri 5 are both -R' ; and A is hydrogen.
  • Ris is R ⁇ -C(0)R ⁇ or -P(0) (OR' ) 2 ;
  • R i4 and Ri 5 are both -R' and R' is (C1-C12 ) -aliphatic- .
  • the present invention provides a compound of formula IE:
  • R ⁇ 6 is -C(0)R', -P(O) (OR') 2 ,; Ri4 and R i5 are both -R' and R' is preferably methyl; A is hydrogen; and Ri, R 2 , R 3 , R 4 , Rs, R5 ' , R7, Rg, Rg-, Rio, Rio-, R11, Rii', and W are as defined in any of the embodiments herein.
  • R 14 and R 15 are both -R' ; and A is hydrogen.
  • U is -NR'-.
  • R 14 and R 15 are both -R' and R' is
  • the present invention provides a compound of formula IF:
  • R' , Ri, R2, R3, R 4 , Rs, s-, R7, Rg, Rg', Rio, Rio-, R11, Rii-, Ri6, Ri8 ' , and W are as defined in any of the embodiments herein.
  • R ⁇ 6 is R' ;
  • R 14 and R 15 are both -R' and R' is preferably methyl;
  • A is hydrogen; and Ri, R 2 , R3, R4, R5, R 5' , R 7 , Rg,
  • Ris and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the R 18 and R ⁇ 8 ⁇ atoms bound to the carbon atom are independently 0 or N; wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, 0, S, SO, and SO2; wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, and a (C3-C10) heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J;
  • Ri6 is R' ;
  • R 14 and R 1 5 are both -R' ;
  • A is hydrogen
  • the Ris and Ri 8 - atoms bound to the carbon atom are 0 and the ring formed when R i8 and R ⁇ 8 - are optionally taken together with the carbon atom to which they are bound optionally contains up to 1 additional oxygen atom and is optionally substituted with up to 2 J substituents.
  • the present invention provides a compound of formula IG:
  • R i6 is R' , R' , Ri, R , R 3 , R4, Rs, R5 ' , R 7 , Rg, Rg-, Rio, Rio-, R11, Rii-, and W are as defined in any of the embodiments herein.
  • the R ⁇ 8 and Ris- atoms bound to the carbon atom are 0; the ring formed when R i8 and R ⁇ 8' are optionally taken together with the carbon atom to which they are bound is a 5- or 6-membered ring system optionally substituted with up to 2 J substituents; Ri 6 is R' ; R 14 and R 15 are both -R' and R' is preferably methyl; A is hydrogen; and R x , R 2 , R 3 , R4, R5, Rs-, R7, Rg, Rg-, Rio, Rio- , R 11 , Rii-, and W are as defined in any of the embodiments herei .
  • this invention does not include compounds wherein T is 3-acetyl-4, 5- dimethyl-lH-pyrrole (e.g., see compounds 63-64 at page 95, and compounds 66-67 at page 96 of WO 03/087092) .
  • this invention does not include compounds wherein: V is -C(O)-, -C(S)-, -S(O)-, or -S(0) 2 - ; and radical T is:
  • R 20 is -H, -S(0)R°, -S(0) 2 R°, -C(0)R°, -C(0)OR°, -C(0)N(R°) 2 , -N(R°)C(0)R°, j-N ( COR° ) COR° , -S0 2 N(R°) 2 , -SO 3 R 0 , -C(0)C(0)R°, -C(0)CH 2 C(0)R°, -C(S)R°, -C(S)N(R°) 2 , -(CH 2 ) 0 - 2 NHC(0)R°, -N(R°)N(R°)COR°, -N(R°)N (R°) C (0) OR°, -N(R°)N(R o )C0N(R o ) 2 , -N(R°)S0 2 R°, -N (R°) S0 2 N(R°) , -N(R°
  • R 21 and R 22 are independently halogen, -0R°, -0C(0)N(R°) 2 , -N0 2 , -CN, -CF 3 , -OCF 3 , -R°, oxo, 1,2- methylenedioxy, 1, 2-ethylenedioxy, -N(R°) 2 , -SR°, -S0R°, -S0 2 R°, -S0 2 N(R°) 2 , -S0 3 R°, -C(0)R°, -C(0)C(0)R°, -C(0)CH 2 C(0)R°, -C(S)R°, -C(0)0R°, -OC(0)R°, -C(0)N(R°) 2/ -OC(0)N(R°) 2 , -C(S)N(R°) 2 , -(CH 2 )o-2NHC(0)R°;
  • R 23 is -0R°, -CF 3 , -OCF3, -R°, -N(R°) 2 , -C(0)R°, or -N(R°)C0R°; two R° groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or non- aromatic ring having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, or S0 2 , wherein the ring is optionally fused to a (C6-C10) aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or a (C3-C10) heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J 3 ; or each R° is independently selected from: hydrogen- , (C1-C12) -aliphatic-,
  • J 3 is halogen, -OR°, -OC (0)N(R°) 2 , -N0 2 , -CN, -CF 3 , -OCF , -R°, oxo, thioxo, 1, 2-methylenedioxy, -N(R°) 2 , -SR°, -SOR°, -S0 2 R°, -S0 2 N(R 0 ) 2 , -S0 3 R°, -C(0)R°, -C(0)C(0)R°, -C(0)CH 2 C(0)R°, -C(S)R°, -C(0)OR°, -0C(0)R°, -C(0)N(R°) 2 , -0C(0)N(R°) 2 , -C(S)N(R°) 2 , -(CH 2 )o- 2 NHC(0)R°, -N(R°)N(R°)C0R°, -N(R°)N
  • R ⁇ 6 is R', -C(0)R', -P(O) (OR') 2, or -SO3R' ;
  • U is 0, or N, or a bond;
  • Ris and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the R ⁇ 8 and Ris- atoms bound to the carbon atom are independently 0 or N; wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, 0, S, SO, and S0 2 ; wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, and a (C3-CIO) heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; provided that when R i8 and Rig- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsatur
  • n 0, 1, or 2;
  • Z and Z' are independently C(H), N, NH, 0, or S;
  • R 9 , Rg-, Rii, and Ru- are as defined in any of the embodiments herein; and the spirocyclic ring containing Z and Z ' is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • Rii and Ru- are both H; n is 0 , 1 , or 2 ;
  • Rg and R 9 - are as defined in any of the embodiments herein; and the spirocyclic ring containing Z and Z' is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • the radical is
  • n 0 or 1.
  • Ri, R 2 , R 3 , R 4 , Rs, R5', R7, Rg, Rg-, R11, Rii', R14, Ris, Rie, Ris, Ris-, n, V, A, U, Z, Z' and W are as defined in any of the embodiments herein.
  • Z and Z' are independently C(H), N, NH, 0, or S; Rg, Rg-, Ri , and Ru- are as defined in any of the embodiments herein; and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • the present invention provides a compound of formula IJ:
  • Ri R 2 , R 3 , R 4 , R 5 , R 5' , R 7 , Rg, Rg-, Ru, Rn-, R14, Ris,
  • Rie, Ris, Ri8 ' , V, A, U, Z, Z' and W are as defined in any of the embodiments herein; and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • Z and Z' are S
  • Rg and Rg- are H, R , R 2 , R 3 , R , R 5 , R 5 ⁇ , R 7 , Ru, Ru-, R 14 , R 15 , Rie, Ris, Ris-,
  • V, A, U, and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • the radical is :
  • R 9 , Rg-, Ru, and Ru- are H.
  • Rg, Rg-, Ru, and Ru- are H.
  • the present invention provides a compound of formula IK:
  • Ri, R 2 , R 3 , R 4 , Rs, s-, R?, Rg, R 9' , Rii, Rii', Ri4, Ris, Ri6, Ris, Ris-, V, A, U, and W are as defined in any of the embodiments herein .
  • R 9 , R 9 , , Rio, Ru, and Ru- are H;
  • Rg , R 9 ⁇ , Rio , Rio- , and Ru are H;
  • Ru- is: (C1-C12 ) -aliphatic- , (C3-C10) -cycloalkyl- or -cycloalkenyl-, (C ⁇ -ClO)-aryl-, wherein any ring is optionally fused to a (C6-Cl0)aryl, (C5-C10)heteroaryl, (C3-C10) cycloalkyl, or (C3-C10) heterocyclyl; wherein up to 3 aliphatic carbon atoms in Ru- may be replaced by a heteroatom selected from 0, NH, S, SO, or S0 2 in a chemically stable arrangement; wherein Ru-, is independently and optionally substituted with up to 3 substituents independently selected from J. [0066] According to another embodiment of compounds of formula I, the
  • Rg, Rio, Ru, and Ru- are H; and R 9 - and Rio- are: '
  • Rg, Rg-, Rio-, Ru, and Ru- are H; and R' is selected from: (C6-C10)-aryl-,
  • Rg, Rg-, Rie, Ru, and Ru- are H; and R' is selected from: (C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10 ) -heterocyclyl- (C1-C12) aliphatic- and (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J.
  • Rg, Rg-, Rie, Ru, and Ru- are H
  • R' is selected from: (C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10 ) -heterocyclyl- (C1-C12) aliphatic- and (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 5 atoms in R' are optionally and independently substitute
  • the present invention provides a compound of formula IL:
  • R ⁇ Ri, R 2 , R 3 , R 4 , Rs, Rs- , Rv, Rg, Rg-, Rn, Rii', Ri4, Ris, Ri6, Ris, Ris-, V, A, U, and W are as defined in any of the embodiments herein.
  • ring A is a 5- to 6-membered aromatic or a 3- to 7-membered non-aromatic ring system having up to 3 heteroatoms independently selected from N, NH, O, SO, or S0 2 ; wherein said ring A is optionally fused to a (C6- Cl0)aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, or (C3- C10) heterocyclyl; > wherein any ring has up to 3 substituents selected independently from J; and
  • Rg, R , Rie, and Ru- are as defined in any of the embodiments herein.
  • the present invention provides a compound of formula IM:
  • ring A is a 5- to 6-membered aromatic or a 3- to 7-membered non-aromatic ring system having up to 3 heteroatoms independently selected from N, NH, 0, SO, or S0 2 ; wherein said ring A is optionally fused to a (C6- Cl0)aryl, (C5-C10) eteroaryl, (C3-CIO) cycloalkyl, or (C3- Cl0 ) heterocyclyl ; wherein any ring has up to 3 substituents selected independently from J; and
  • R9 ' , Rio ' , Ru, and Ru- are as defined in any of the embodiments herein.
  • the present invention provides a compound of formula IN:
  • Ri, R 2 , R3, R4, Rs, R5', R7, Rg', Rio, Rii', R11, R14, R15, Ri6, Ris, Ri8 ' , V, A, U, W, and ring A are as defined in any of the embodiments herein.
  • 1 ring B forms a 3- to a 20-membered carbocyclic or heterocyclic ring system; wherein each ring B is either aromatic or nonaromatic; wherein each heteroatom in the heterocyclic ring system is N, NH, O, SO, or S0 2 ; wherein ring B is optionally fused to a (C6- Cl0)aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or (C3- Cl0) heterocyclyl; wherein each ring has up to 3 substituents selected independently from J; and
  • Rg- and Ru- are as defined in any of the embodiments herein. [0086] According to another embodiment, the
  • the present invention provides a compound of formula 10:
  • Ri, R , R 3 , R4, Rs, Rs-, R7, Rg', Rii', Ri4, Ris, Ri6, Ris, Ris-, V, A, U, W, and ring B are as defined in any of the embodiments herein .
  • W in compounds of formula I is :
  • the NR ⁇ R ⁇ is selected from -NH- (C1-C6 aliphatic), -NH-(C3-C6 cycloalkyl), -NH-CH (CH 3 ) -aryl, or -NH-CH(CH 3 ) -heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with up to 3 halogens .
  • the RgR ⁇ in the W radical is:
  • R 6 R6 in the W radical is:
  • the NR ⁇ R ⁇ is
  • the NR 6 R 6 is
  • the NR ⁇ R ⁇ in the W radical is:
  • the NR 6 R6 in the W radical is:
  • the present invention provides a compound of formula IP:
  • Ri, R , R3, R4, Rs, Rs-, R ⁇ , R7, Rg, Rg-, Rio, Rie, R11, Rii ' , Ri4, Ris, Ri6, Ris, Ri8 ' , V, A, and U are as defined in any of the embodiments herein.
  • W in compounds of formula I is :
  • R 8 wherein R 8 is as defined above.
  • each R 8 together with the boron atom is a (C5-CIO) -membered heterocyclic ring having no additional heteroatoms other than the boron and the two oxygen atoms.
  • Preferred groups are selected from:
  • R' is, preferably, (C1-C6) -aliphatic and is, more preferably, methyl.
  • R 5 > is hydrogen and R 5 is:
  • R 5 > is hydrogen and R 5 is:
  • the present invention provides a compound of formula IQ :
  • Ri, R 2 , R 3 , R 4 , Re, R7, Rg, Rg', Rio, Rie, R11, Rii', Ri4, Ris, Ris, R i8, Ris-, V, A, and U are as defined in any of the embodiments herein .
  • R 2 , R 4 , and R 7 are each independently H, methyl , ethyl , or propyl .
  • R 2/ R4, and R 7 are each H.
  • the present invention provides a compound of formula IR:
  • Ri, R 2, R3, R4, Re, R7, R9, R9', Rio, Rio-, R11, Ru-, R14, R15, Rie, is, Ris-, V, A, and U are as defined in any of the embodiments herein.
  • NRsR ⁇ is:
  • R 3 is :
  • R 3 is :
  • R 3 is :
  • the present invention provides a compound of formula IS :
  • Ri, R 6 , Rg, Rg-, Rio, Rio- , Ru, Ru-, Ri4, Ris, Ri6, Ris, Ris-, V, A, and U are as defined in any of the embodiments herein.
  • Ri is :
  • Ri is:
  • Ri is cyclohexyl .
  • the present invention provides a compound of formula IT:
  • R ⁇ , Rg, Rg-, Rio, RlO', Rll, Rll', Rl4, Rl5, Rl ⁇ , Rl8, Rl8 ' , V, A, and U are as defined in any of the embodiments herein.
  • R 6 , Rg, Rg-, Rio, Rio ' , Ru, Ru-, and R 12 are as defined in any of the embodiments herein, and NR 5 R6 is: H ⁇ .
  • R i4 and R ⁇ 5 are both -R' and R' is - (C1-C6 aliphatic) . More preferably, R 14 and R 15 are both methyl .
  • the compounds of this invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be of the R or S configuration.
  • the compounds of this invention have the structure and stereochemistry depicted in formulae IA-IT.
  • any of the preferred embodiments recited herein, including those embodiments in the above species, may define formula I individually or be combined to produce a preferred embodiment of this invention.
  • the compounds of this invention contain, and may be modified to contain, appropriate functionalities to enhance selective biological properties compared to the corresponding parent compound. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system) , increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion. [0122] Without being bound by theory, we believe the compounds of this invention may enhance biological, properties by behaving as prodrugs .
  • NMM N-methylmorpholine
  • NMP N-meth lpyyrolidinone
  • Boc 2 0 di-tert-butyldicarbonate
  • Cbz benzyloxycarbonyl
  • TBAF tetrabutylammonium fluoride
  • Chg cyclohexylglycine
  • t-BG tert-butylglycine
  • mCBPA 3-chloroperoxybenzoic acid
  • TEMPO 2 , 2, 6, 6-tetramethyl-l-piperidinyloxy, free radical
  • PyBOP tris (pyrrolidino)bromophosphonium hexafluorophosphate
  • the compounds of this invention may be prepared in general by methods known to those skilled in the art. Advantageously, these compounds are conveniently synthesized from readily available starting materials. Schemes 1-17 below illustrate synthetic routes to the compounds of the present invention. [0128] As can be appreciated by the skilled artisan, the synthetic schemes shown are not intended to comprise a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized. Other equivalent schemes, which will be readily apparent to the ordinary skilled organic chemist, may alternatively be used to synthesize various portions of the molecule as illustrated by the general schemes below. Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds . Other equivalent schemes, which will be readily apparent to the ordinary skilled organic chemist, may alternatively be used to synthesize various portions of the molecule as illustrated by the general schemes below, and the preparative examples that follow.
  • Scheme 1 above provides a general route for the preparation of compounds of formula I and IA-1, wherein V is -C(O), W is -C(0)C(0) -N(R 6 ) 2 , R 2 , R 4 , and R 7 are H, and Ri, R 3 , R 5 , Rs-, Re, Rg, R 9 ', Rio, R ⁇ o ⁇ , R11, Rii', R12, R12', R14, Ris, Rie, Ris, Ris-, A, and U are as described in any of the embodiments herein. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediates 3, 5, 7, and 10.
  • Cbz protected amino acids represented by, for instance, Cbz-Ri-OH
  • Cbz-Ri-OH may alternatively be substituted with the commercial t-Boc protected amino acids .
  • Suitable deprotection conditions to remove the Boc protecting groups are known to those skilled in the art.
  • the oxidation of intermediate 10 to compounds of formula IA-1 may be accomplished using other suitable conditions known to the skilled artisan.
  • Intermediate 2 may be prepared according to the procedures described by Schoellkopf, et al., Justus Liebigs Alia . Chem . GE, pp. 183-202 (1976) and Stemple et al . , Organic Letters, 2(18), pp. 2769-2772 (2000) .
  • Intermediate pyrrole acid 9 may be prepared according to the methods described in the schemes below starting from commercially available starting materials.
  • V is -C(O)
  • W is -C(0)C(0) -N(R 6 ) 2
  • U is a bond
  • A is -C(R ⁇ 2 ) (R ⁇ 2' )-T-R ⁇ 3 wherein R 12 is hydrogen, R i2' is CH, T is oxygen and R ⁇ 3 is -C(0)R', R2, R 4 , and R 7 are H
  • R' , R i# R 3 , R 5 , R 5 -, R 6 , R 9 , R 9 ⁇ , R 0 , Rie, R11, Rii', Ri 2 , R12 ' , Ri4, R15, and Ri ⁇ are as described in any of the embodiments herein.
  • Rii ' , R12, R12 ' , Ri4, and R15 are as described in any of the embodiments herein.
  • Scheme 12 above in combination with scheme 1 above provides a general route for the preparation of compounds of formula I and IH wherein V is -C(O), W is - C(0)C(0) -N(R 6 )2, R 2 , R4, and R 7 are H, and R i; R 3 , R 5 , R5 ' , Re , R 9 , R9', R11, Rii', R12, R12', R i4, R15, Ri ⁇ , Ris, Ris' , n., A, U, Z, and Z' are as described in any of the embodiments herein.
  • Scheme 12 above in combination with scheme 1 also provides a general route for the preparation of compounds of formula I and IK using modifications (e.g. other appropriate commercially available starting materials) known to those skilled in the art.
  • Scheme 13 above in combination with scheme 1 above provides a general route for the preparation of compounds of formula I and IK wherein V is -C(O) , W is - C(0)C (0) -N(R 6 )2, R 2 , R4, and R 7 are H, Rio, and Rio- are fluoro, and R x , R 3 , R 5 , R 5 -, Re, R 9 , R 9 -, R11, Ru-, R ⁇ 2 , R12 ' , R14, R15, Rie, Ris, Ris-, A, and U, are as described in any of the embodiments herein.
  • Scheme 14 above provides a general route for the preparation of compounds of formula I, IL, and IL-1 wherein V is -C(O), W is -C (0) C (O) -N(R 6 )2, R 2 , R4, R7, Rg, R 9 » Rio-, Rii * and Ru-, are H, Rio- is OR 1 , and Ri, R 3 , R5, ⁇ ' i R6 Ri4 ⁇ R15, Ri6, Ris, is-, A, and U, are as described in any of the ' embodiments herein. As would be appreciated by any skilled practitioner, compound 67 may be carried on to compounds of formula IL-1 by routine methods .
  • Scheme 15 above depicts an alternative approach to preparing compounds of formula IL and IL-1 of this invention wherein V is -C ' (O), W is -C (0) C (0) -N(R 6 ) 2 , R 2 , R 4 , R 7 , R 9 , Rg , , Rie Ru, and Ru-, are H, R i0' is OR', and Ri, R 3 , R 5 , R5', Re, Ri4, Ris, Rie, Ris, Ris-, A, and U, are as described in any of the embodiments herein.
  • a 4-hydroxyproline derivative 69 is reacted with a commercially available R' -halide (such an aryl chloride), represented by R'-X, in the presence of a suitable base (such as potassium t-butoxide) to provide a compound 70.
  • R' -halide such an aryl chloride
  • R'-X a suitable base
  • compound 70 may be carried on to compounds of formula IE-1 by routine methods.
  • other suitable and commercially available coupling reagents may be used I to prepare intermediates 72, 73, 7 ff and 75.
  • Scheme 16 in combination with scheme 1 above provides a general route for the preparation of compounds of formula IM, and IM-1 wherein V is -C(O), W is - C(0)C(0)-N(R 6 ) 2 , 2, R4, R7, R9, Rg-, Rio-, and Ru., are H, Rio and Ru are taken together with the ring atoms to which they are bound to form a ring system as defined in any of the embodiments and Ri, R 3 , R 5 , R 5' , Re , R ⁇ , R15, Rie, Ris, Ris-, A, and U, are as described in any of the embodiments herein.
  • Bicyclic starting materials such as compound 76 may be any commercially available reagents of interest or may be synthesized according to literature methods known to the skilled artisan. After coupling of 76 to intermediate 2, resulting intermediate 80 may be carried on to compounds of formula IM-1 by the methods described in scheme 1.
  • Scheme 16 in combination with scheme 1
  • Scheme 17 above provides a synthetic route for the preparation of Cbz-protected azabicyclo [2.2. l]heptane-3-carboxylic acid, compound 33 and the corresponding t-butyl ester, compound 84.
  • the free acid 83 may be further elaborated by the route defined in scheme 1 above to prepare compounds of formula I and 10.
  • the preparation of various other optionally substituted multicyclic azaheterocyclyls intermediates to prepare compounds of formulae I and IN via schemes 1, 14 or 15 above, may be accomplished by the methods described in PCT publication No. WO 02/18369 and references cited therein.
  • Various 3, 4, and 5-substituted proline analogues may either be purchased commercially or prepared according to known literature procedures .
  • the starting 3-substituted proline analogues may be prepared according to the method of Holladay, M.W. et al . , J. Med. Chem. , 34, pp. 457-461 (1991).
  • the cyclohexyl proline intermediates may be prepared by platinum oxide reduction of the commercially available phenyl substituted proline analogues. Such reduction conditions are well known to those skilled in the art.
  • R 9 - is (C1-C12) -aliphatic- and Rio- is (C1-C12 ) -aliphatic-
  • the starting 3 , 4-disubstituted proline analogues may be prepared according to t e method of Kanamasa, S. et al . , J " . Org. Chem, 56, pp.
  • one embodiment of this invention provides a process for preparing a compound of formula I, as defined in any of the embodiments herein, comprising the step of: reacting a compound of formula VII in the presence of a compound of formula VIII ,to provide a compound of formula IX:
  • R 2 ⁇ is an amine protecting group, a P3- residue of an HCV protease inhibitor described herein, or a P4-P3- residue of an HCV protease inhibitor as described herein, and wherein the P3 and the P4-P3 residues are optionally protected with an amino-terminal capping group;
  • R 20 is a carboxy protecting group or a Pi residue of an HCV protease inhibitor described herein, wherein the Pi residue is optionally protected with a carboxy terminal protecting group or with W.
  • R' is as defined in any of the embodiments herein.
  • X is an appropriate leaving group. As would be appreciated by skilled practitioners, an appropriate leaving group may be generated in situ. [0150] In an alternative embodiment, the 4-hydroxy group in formula VII may be converted to a leaving group. In such an embodiment, X is a nucleophilic oxygen which reacts with VII to provide IX.
  • Pi, P3 , P4 refer to the residues of an HCV protease inhibitor as defined in the art and as are well known to -skilled practitioners.
  • the compound of formula IX may be carried on to a compound of formula I according to the methods described herein.
  • compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof.
  • the compound of formula I is present in an amount effective to decrease the viral load in a sample or in a patient, wherein said virus encodes a serine protease necessary for the viral life cycle, and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable salts of the compounds of this invention are utilized in these compositions, those salts are preferably derived from inorganic or organic acids and bases .
  • acid salts include the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate,
  • Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others . Water or oil-soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides
  • dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides
  • compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties.
  • modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or ⁇ electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers , polyethylene glycol and wool fat .
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate
  • compositions of this invention are formulated for pharmaceutical administration to a mammal, preferably a human being.
  • Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides .
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically- acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions .
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions .
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of antiviral, particularly anti-HCV mediated disease.
  • the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w) .
  • compositions of this invention comprise a combination of a compound of formula I and one or more additional therapeutic or prophylactic agents
  • both the compound and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers that are commonly used include lactose and corn starch.
  • Lubricating agents, such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers .
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical compositions may be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents .
  • Most preferred are pharmaceutical compositions formulated for oral administration.
  • compositions of this invention additionally comprise another agent, preferably a cytochrome P-450 inhibitor.
  • cytochrome P-450 inhibitors include, but are not limited to, ritonavir.
  • compositions of this invention additionally comprise another anti-viral agent, preferably an anti-HCV agent.
  • anti-viral agents include, but are not limited to, immunomodulatory agents, such as -, ⁇ -, and ⁇ -interferons, pegylated derivatized interferon- compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors) ; inhibitors of other targets in the HCV life cycle, including helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., VX-497 and other IMPDH inhibitors disclosed in United States Patents 5,807,876 and
  • a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms .
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the , activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of active ingredients will also depend upon the particular described compound and the presence or absence and the nature of the additional anti-viral agent in the composition.
  • the invention provides a method for treating a patient infected with a virus characterized by a virally encoded serine protease that is necessary for the life cycle of the virus by administering to said patient a pharmaceutically acceptable composition of this invention.
  • the methods of this ' invention are used to treat a patient suffering from a HCV infection. Such treatment may completely eradicate the viral infection or reduce the severity thereof. More preferably, the patient is a human being.
  • the methods of this invention additionally comprise the step of administering to said patient an anti-viral agent preferably an anti- HCV agent.
  • anti-viral agents include, but are not limited to, immunomodulatory agents, such as ⁇ -, ⁇ -, and ⁇ -interferons, pegylated derivatized interferon- ⁇ compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors) ; inhibitors of other targets in the HCV life cycle, including but not limited to helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., VX-497. and other IMPDH inhibitors disclosed in United States Patents 5,807,876 and 6,498,178, mycophenol
  • Such additional agent may be administered to said patient as part of a single dosage form comprising both a compound of this invention and an additional antiviral agent.
  • the additional agent may be administered separately from the compound of this invention, as part of a multiple dosage form, wherein said additional agent is administered prior to, together with or following a composition comprising a compound of this invention.
  • the present invention provides a method of pre-treating a biological substance intended for administration to a patient comprising the step of contacting said biological substance with a pharmaceutically acceptable composition comprising a compound of this invention.
  • Such biological substances include, but are not limited to, blood and components thereof such as plasma, platelets, subpopulations of blood cells and the like; organs such as kidney, liver, heart, lung, etc; sperm and ova; bone marrow and components thereof, and other fluids to be infused into a patient such as saline, dextrose, etc.
  • the invention provides methods of treating materials that may potentially come into contact with a virus characterized by a virally encoded serine protease necessary for its life cycle.
  • This method comprises the step of contacting said material with a compound according to the invention.
  • materials include, but are not limited to, surgical instruments and garments (e.g. clothes, gloves, aprons, gowns, masks,, eyeglasses, footwear, etc.); laboratory instruments and garments (e.g. clothes, gloves, aprons, gowns, masks, eyeglasses, footwear, etc.); blood collection apparatuses and materials; and invasive devices, such as shunts, stents, etc.
  • the compounds of this invention may be used as laboratory tools to aid in the isolation of a virally encoded serine protease.
  • This method comprises the steps of providing a compound of this invention attached to a solid support; contacting said solid support with a sample containing a viral serine protease under conditions that cause said protease to bind to said solid support; and eluting said serine protease from said solid support.
  • the viral serine protease isolated by this method is HCV NS3-NS4A protease.

Abstract

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

Description

INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of United States Provisional Application number 60/510,317, filed October 10, 2003, entitled "Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease", the entire contents of which is hereby incorporated by reference. This application also claims the benefit of United States Patent Application number 10/412,600, filed April 11, 2003, entitled "Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease", the entire contents of which is hereby incorporated by reference.
TECHNICAL FIELD OF THE INVENTION
[0002] The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents . The invention further relates to pharmaceutical compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to processes for preparing the compounds and methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
BACKGROUND OF THE INVENTION [0003] Infection by hepatitis C virus ("HCV") is a compelling human medical problem. HCV is recognized as the causative agent for most cases of non-A, non-B hepatitis, with an estimated human sero-prevalence of 3% globally [A. Alberti et al . , "Natural History of Hepatitis C, " J. Hepatology, 31., (Suppl. 1), pp. 17-24 (1999)]. Nearly four million individuals may be infected in the United States alone [M.J. Alter et al . , "The Epidemiology of Viral Hepatitis in the United States, Gastroenterol. Clin. North Am. , 23, pp. 437-455 (1994); M. J. Alter "Hepatitis C Virus Infection in the United States," J. Hepatology, 31., (Suppl. 1), pp. 88-91 (1999)] .
[0004] Upon first exposure to HCV only about 20% of infected individuals develop acute clinical hepatitis while others appear to resolve the infection spontaneously. In almost 70% of instances, however, the virus establishes a chronic infection that persists for decades [S. Iwarson, "The Natural Course of Chronic Hepatitis," FEMS Microbiology Reviews, 14, pp. 201-204 (1994) ; D. Lavanchy, "Global Surveillance and Control of Hepatitis C, " J. Viral Hepatitis, 6, pp. 35-47 (1999)]. This usually results i recurrent and progressively worsening liver inflammation, which often leads to more severe disease states such as cirrhosis and hepatocellular carcinoma [M.C. Kew, "Hepatitis C and Hepatocellular Carcinoma", FEMS Microbiology Reviews, 14, pp. 211-220 (1994); I. Saito et . al . , "Hepatitis C Virus Infection is Associated with the Development of Hepatocellular Carcinoma, " Proc. Natl . Acad. Sci. USA, 87, pp. 6547-6549 (1990)]. Unfortunately, there are no broadly effective treatments for the debilitating progression of chronic HCV.
[0005] The HCV genome encodes a polyprotein of 3010- 3033 amino acids [Q.L. Choo, et. al . , "Genetic Organization and Diversity of the Hepatitis C Virus." Proc. Natl. Acad. Sci. USA, 88, pp. 2451-2455 (1991); N. Kato et al . , "Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis," Proc. Natl. Acad. Sci. USA, 87, pp. 9524-9528 (1990); A. Takamizawa et. al . , "Structure and
Organization of the Hepatitis C Virus Genome Isolated From Human Carriers," J. Virol. , 65, pp. 1105-1113 (1991) ] . The HCV nonstructural (NS) proteins are presumed to provide the essential catalytic machinery for viral replication. The NS proteins are derived by proteolytic cleavage of the polyprotein [R. * Bartenschlager et. al . , "Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions," J. Virol., 67, pp. 3835-3844 (1993); A. Grakoui et. al . , "Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites," J. Virol . , 67, pp. 2832-2843 (1993); A. Grakoui et. al . , "Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products," J. Virol . , 67, pp. 1385-1395 (1993); L. Tomei et . al . , "NS3 is a serine protease required for processing of hepatitis C virus polyprotein", J. Virol . , 67, pp. 4017-4026 (1993)]. [0006] The HCV NS protein 3 (NS3 ) contains a serine protease activity that helps process the majority of the viral enzymes, and is thus considered essential for viral replication and infectivity. It is known that mutations in the yellow fever virus NS3 protease decrease viral infectivity [Chambers, T.J. et. al . , "Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein", Proc. Natl. Acad. Sci. USA, 87, pp. 8898-8902 (1990)]. The first 181 amino acids of NS3 (residues 1027-1207 of the viral polyprotein) have been shown to contain the serine protease domain of NS3 that processes all four downstream sites of the HCV polyprotein [C. Lin et al . , "Hepatitis C Virus NS3 Serine Proteinase: Trans-Cleavage
Requirements and Processing Kinetics", J. Virol . , 68, pp. 8147-8157 (1994)].
[0007] The HCV NS3 serine protease and its associated cofactor, NS4A, helps process all of the viral enzymes, and is thus considered essential for viral replication. This processing appears to be analogous to that carried out by the human immunodeficiency virus aspartyl protease, which is also involved in viral enzyme processing. HIV protease inhibitors, which inhibit viral protein processing, are potent antiviral agents in man, indicating that interrupting this stage of the viral life cycle results in therapeutically active agents . Consequently HCV NS3 serine protease is also an attractive target for drug discovery. [0008] Several potential HCV protease inhibitors have been described [PCT publication Nos. WO 02/18369, WO 02/08244, WO 00/09558, WO 00/09543, WO 99/64442, WO 99/07733, WO 99/07734, WO 99/50230, WO 98/46630, WO 98/17679 and WO 97/43310, United States Patent 5,990,276, M. Llinas-Brunet et al . , Bioorg. Med. Chem. Lett., 8, pp. 1713-18 (1998); W. Han et al . , Bioorg. Med. Chem. Lett., 10, 711-13 (2000); R. Dunsdon et al . , Bioorg. Med. Chem. Lett. , 10, pp. 1571-79 (2000); M. Llinas-Brunet et al . , Bioorg. Med. Chem. Lett., 10, pp. 2267-70 (2000); and S . LaPlante et al . , Bioorg. Med. Chem. Lett., 10, pp. 2271- 74 (2000)].
[0009] Furthermore, the current understanding of HCV has not led to any other satisfactory anti-HCV agents or treatments. Until recently, the only established therapy for HCV disease was interferon treatment. However, interferons have significant side effects [M. A. Wlaker et al . , "Hepatitis C Virus: An Overview of Current Approaches and Progress," DDT, 4, pp. 518-29 (1999); D. Moradpour et al . , "Current and Evolving Therapies for Hepatitis C, " Eur. J. Gastroenterol . Hepatol . , 11, pp. 1199-1202 (1999); H. L. A. Janssen et al . "Suicide Associated with Alfa-Interferon Therapy for Chronic Viral Hepatitis," J. Hepatol., 21, pp. 241-243 (1994); P.F. Renault et al . , "Side Effects of Alpha Interferon,"
Seminars in Liver Disease, 9, pp. 273-277. (1989)] and induce long term remission in only a fraction (~ 25%) of cases [0. Weiland, "Interferon Therapy in Chronic Hepatitis C Virus Infection", FEMS Microbiol. Rev., 14, pp. 279-288 (1994)]. Recent introductions of the pegylated forms of interferon (PEG-Intron® and Pegasys®) and the combination therapy of ribavirin and pegylated interferon (Rebetrol®) have resulted in only modest improvements in remission rates and only partial reductions in side effects. Moreover, the prospects for effective anti-HCV vaccines remain uncertain. [0010] Thus, there is a need for more effective anti- HCV therapies . Such inhibitors would have therapeutic potential as protease inhibitors, particularly as serine protease inhibitors, and more particularly as HCV NS3 protease inhibitors. Specifically, such compounds may be useful as antiviral agents, particularly as anti-HCV agents .
SUMMARY OF THE INVENTION
[0011] The present invention provides a compound of formula I :
Figure imgf000007_0001
or a pharmaceutically acceptable salt thereof, wherein :
R9 and Rg< are each independently: hydrogen- , (C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12) - aliphatic-, (C6-Cl0)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10) -heterocyclyl-,
(C3-C10) -heterocyclyl- (C1-C12) aliphatic-, (C5-C10) -heteroaryl-, or (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to three aliphatic carbon atoms in each of Rq and R9< are optionally replaced by 0, N, NH, S, SO, or S02 in a chemically stable arrangement; wherein each of Rg and R9< is independently and optionally substituted with up to 3 substituents independently selected from J;
J is halogen, -OR', -N02, -CN, -CF3, -0CF3, -R' , oxo, t ioxo, =N(R'), =N(0R'), 1, 2-methylenedioxy, 1,2- ethylenedioxy, -N(R')2, -SR' , -SOR', -S02R", -S02N(R')2, -S03R', -C(0)R', -C(0)C(0)R', -C (0) C (0) OR' , -C(0)C(0)N(R' )2, -C(0)CH2C(0)R' , -C(S)R', -C(S)0R\ -C(0)0R', -0C(0)R', -C(0)N(R')2, -OC (0)N (R ' ) 2, -C(S)N(R')2, -(CH2)0-2NHC(O)R' , -N (R' ) N (R' ) COR' , -N(R' )N(R' )C(0)OR' , -N(R' )N(R' )CON(R' )2, -N(R')S02R', -N(R')S02N(R' )2, -N(R')C(0)OR' , -N (R ' ) C (0) R' , -N(R' )C(S)R' , -N(R' )C(0)N(R* )2, -N(R' ) C (S)N (R ' ) 2, -N(C0Rr )COR' , -N(OR')R', -C (=NH)N (R ' ) 2, -C (0)N (OR ' ) R ' , -C(=NOR')R\ -OP(O) (OR')2, -P(0) (R')2, -P(0) (OR')2, or -P(O) (H) (OR' ) ; wherein; each R' is independently selected from: hydrogen- , (C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12) - aliphatic-,
(C6-Cl0)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10 ) -heterocyclyl- ,
(C3-C10) -heterocyclyl- (C1-C12) aliphatic-, (C5-C10) -heteroaryl-, and (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J; wherein two R' groups bound to the same atom optionally form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, and S02, wherein said ring is optionally fused to a (C6-C10) aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or a (C3-C10) heterocyclyl, wherein any ring has up to 3 substituents selected independently from J; Rio/ io'/ Rii and Rn- are each independently: hydrogen- ,
(C1-C12) -aliphatic-, (C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12 ) - aliphatic-,
(C6-Cl0)-aryl-,
(C6-C10) -aryl- (C1-C12 ) aliphatic-,
(C3-C10) -heterocyclyl-,
(C3-C10) -heterocyclyl- (C1-C12) aliphatic-,
(C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein any ring is optionally fused to a (C6-C10)aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or (C3-CIO)heterocyclyl; : wherein up to 3 aliphatic carbon atoms in each of R10, IOΆ Rii/ and Rn< are optionally replaced by a heteroatom selected from O, NH, S, SO, or S0 in a chemically stable arrangement; wherein each of Rio, Rio-, Rn, and Ru< is independently and optionally substituted with up to 3 substituents independently selected from J; or is -OR' and Rio- is H; or and Rio- are both -OR' or -SR'; or and Rio- are both fluorine; or , and Rio- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the Rio and Rio- atoms bound to the carbon atom are independently C(H), N, NH, 0, S, SO, or S02; wherein said ring optionally contains up to 4 heteroatoms independently selected from N, NH, 0, S, SO, and S02; wherein any atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; and wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, and a (C3-C10) eterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; or R9 and Rio are optionally taken together with the ring atoms to which they are bound to form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system up to 3 heteroatoms independently selected from N, NH, 0, S, SO, or S02; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; or Rio and Rn are *:optionally taken together with the ring atoms to which they are bound to form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, or S02; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or R9 and Rii are optionally taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic or heterocyclic ring system containing up to 10 atoms; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; wherein each heteroatom in the heterocyclic ring system is selected from the group consisting of N, NH, 0, S, SO, or S02; Ri and R3 are each independently:
(C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl-,
[ (C3-C10) -cycloalkyl- or -cycloalkenyl] - (C1-C12) - aliphatic-,
(C6-C10) -aryl- (C1-C12) aliphatic-, or
(C5-C10) -heteroaryl- (C1-C12 ) -aliphatic- ; wherein up to 3 aliphatic carbon atoms in each of Ri and R3 are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, or S0 in a chemically stable arrangement; wherein each of Ri and R3 is independently and optionally substituted with up to 3 substituents independently selected from J; R, R4, and R are each independently: hydrogen- ,
(C1-C12 ) -aliphatic- ,
(C3-C10 ) -cycloalkyl- (C1-C12 ) -aliphatic- , or (C6-C10) -aryl- (C1-C12 ) -aliphatic-; wherein up to two aliphatic carbon atoms in each of R2, R, and R7 are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, and S02 in a chemically stable arrangement; wherein each of R, R4, and R7 is optionally substituted with up to 3 substituents independently selected from J; R5 and R5. are each independently hydrogen or (C1-C12)- aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R5 is optionally substituted with sulfhydryl or hydroxy; or R5 is Ph or -CH2Ph and R5< is H, wherein said P or -CH2Ph group is optionally substituted with up to 3 substituents independently selected from J; or R5 and R5. together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, 0, SO, and S02; wherein said ring is optionally substituted with up to 2 substituents selected independently from J; W is :
Figure imgf000012_0001
Figure imgf000012_0002
wherein m is 0 or 1; wherein each Re is independently: hydrogen- , (C1-C12) -aliphatic-, (C6-C10)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10) -cycloalkyl- or cycloalkenyl-, [ (C3-C10) -cycloalkyl- or cycloalkenyl] - (C1-C12) - aliphatic-,
(C3-C10) -heterocyclyl- ,
(C3-C10) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10) -heteroaryl-, or (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 3 aliphatic carbon atoms in each R6 is optionally replaced by a heteroatom selected from 0, NH, S, SO, or S0 in a chemically stable arrangement; wherein R6 is optionally substituted with up to 3 J substituents; or two Rε groups, together with the nitrogen atom to which they are bound, optionally form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, and S0 , wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10) cycloalkyl, or a (C3-CIO) heterocyclyl, wherein any ring has up to 3 substituents selected independently from J; wherein each Rs is independently -OR' ; or the Rs groups together with the boron atom, is a (C3-C10)- membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N, NR' , 0, SO, and S02; V is -C(0)-, -C(S)-, -S(0)-, or -S(0)2-; A is hydrogen or -C(RX2) (Rι2< ) -T-Ri3; T is oxygen or a bond; R12 and Ri2 > are each independently : hydrogen- , or
(C1-C6 ) -aliphatic- ; wherein up to two aliphatic carbon atoms in each of
R12 and Ri2< are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, and S02 in a chemically stable arrangement; or R12 is absent and Rι2- is =0;
Ri3 is -C(0)R', -P(0)(OR')2, -S03R', -R', or R19; R19 is : hydrogen, \
(C1-C12) -aliphatic-,
(C6-C10) -aryl- (C1-C12 ) aliphatic-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein Ri9 is optionally substituted with up to 3 J substituents ; wherein up to 3 aliphatic carbon atoms in each Rι9 are optionally replaced by a heteroatom selected from
0, NR19, S, SO, or S02 in a chemically stable arrangement; wherein up to 3 aliphatic carbon atoms in each R19 are optionally replaced with -C(0)-;: wherein Rι9 is optionally substituted with up to 3 J substituents ; wherein any NR19, taken together with the nitrogen and a carbon adjacent to the nitrogen, optionally forms a 5- to 7-membered ring system, wherein said ring system optionally contains up to three additional heteroatoms selected from 0, N, NH, S, SO, and S02 in a chemically stable arrangement; R14 and R15 are independently halogen, -OR', -0C (O)N(R' ) 2,
-N02, -CN, -CF3, -OCF3, -R', 1,2-methylenedioxy, 1,2- ethylenedioxy, -N(R')2, -SR' , -S0R\ -S02R' , -S02N(R')2,
-SO3R', -C(0)R', -C(0)C(0)R', -C(0)CH2C(0)R' , -C(S)R*, -C(0)OR\ -OC(0)R', -C(0)N(R')2, -OC (O)N(R' ) 2, -C(S)N(R')2, or -(CH2)0-2NHC(0)R' ; Rie is R', -C(0)R', -P(0)(0R')2, or -S03R' ; U is 0, N, or a bond;
Ris and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the Ris and Ris- atoms bound to the carbon atom are independently 0 or N; wherein said ring optionally contains up to 1 '. additional heteroatom selected from N, NH, 0, S, SO, and S02; wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, and a (C3-CIO)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; provided that when Ris and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system, then Rι6 is R' ; or Rιs< is =0, =CH2, =N(R'), or =N(0R') and Rι8 is absent, provided that when R18 is absent and Ris- is =CH2, then U is oxygen; and provided that when Rι8 is absent and Ris- is =0, =N(R') or =N(0R' ) , then U is a bond and RX6 is R' .
[0012] The invention also relates to processes for preparing the above compounds and to compositions that comprise the above compounds and the use thereof. Such compositions may be used to pre-treat invasive devices to be inserted into a patient, to treat biological samples, such as blood, prior to administration to a patient, and for direct administration to a patient. In each case the composition will be used to inhibit HCV replication and to lessen the risk of or the severity of HCV infection.
DETAILED DESCRIPTION OF THE INVENTION
[0013] The present invention provides a compound of formula I:
Figure imgf000016_0001
I or a pharmaceutically acceptable salt thereof, wherein: R9 and Rg» are each independently: hydrogen- ,
(C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-,
[ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12 ) aliphatic-,
(C6-Cl0)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-,
(C3-C10) -heterocyclyl-,
(C3-C10) -heterocyclyl- (C1-C12) aliphatic-,
(C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to three aliphatic carbon atoms in each of Rg and Rg- are optionally replaced by 0, N, NH, S, SO, or S02 in a chemically stable arrangement; wherein each of Rg and Rg- is independently and optionally substituted with up to 3 substituents independently selected from J;
J is halogen, -OR', -N02, -CN, -CF3, -OCF3, -R' , oxo, thioxo, =N(R'), =N(0R'), 1,2-methylenedioxy, 1,2- ethylenedioxy, -N(R')2, -SR', -SOR', -S02R' , -S02N(R')2, -S03R', -C(0)R', -C(0)C(0)R', -C (O) C (0) OR' , -C(0)C(0)N(R')2, -C(0)CH2C(0)R' , -C(S)R', -C(S)OR\ -C(0)0R', -OC(0)R', -C(0)N(R')2, -OC (O)N(R' ) 2, -C(S)N(R')2, -(CH2)o-2NHC(0)R' , -N (R' ) N (R' ) COR ' , -N(R' )N(R' )C(0)OR' , -N(R' )N(R' )C0N(R' )2, -N(R')S02R', -N(R' )S02N(R' )2, -N(R' )C(0)OR' , -N(R' ) C (O)R' , -N(R' )C(S)R' , -N(R')C(0)N(R')2, -N(R" )C (S)N(R' ) 2, -N(C0R' )COR' , -N(0R')R', -C (=NH) N (R ' ) 2, -C (O)N(OR' ) R1 , -C(=NOR')R', -OP(O) (OR1 )2 -P(0)(R')2, -P(0)(OR')2, or -P(O) (H) (OR' ) ; wherein; each R' is independently selected from: hydrogen- ,
(C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-,
[ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12) - aliphatic- ,
(C6-Cl0)-aryl-,
(C6-C10) -aryl- (C1-C12 ) aliphatic-,
(C3-C10) -heterocyclyl-,
(C3-C10 ) -heterocyclyl- (C1-C12 ) aliphatic- ,
(C5-C10) -heteroaryl-, and
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J; wherein two R' groups bound to the same atom optionally form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and S02, wherein said ring is optionally fused to a (C6-C10) aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or a (C3-CIO) heterocyclyl, wherein any ring has up to 3 substituents selected independently from J; Rio, Rio-/ ii/ and R < are each independently: hydrogen- ,
(C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-CIO) -cycloalkyl or -cycloalkenyl] - (C1-C12) - aliphatic-, (C6-C10)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10) -heterocyclyl-,
(C3-C10) -heterocyclyl- (C1-C12) aliphatic-, (C5-C10) -heteroaryl-, or (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; , wherein any ring is optionally fused to a (C6-Cl0)aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, or (C3-CIO) heterocyclyl; wherein up to 3 aliphatic carbon atoms in each of io/ Rio-/ Rii/ a ii' are optionally replaced by a heteroatom selected from 0, NH, S, SO, or S02 in a chemically stable arrangement; wherein each of Rio, Rio', Rii/ and Rn- is independently and optionally substituted with up to 3 substituents independently selected from J; or Rio is -OR' and Rι0< is H; or Rio and Rio- are both -OR' or -SR'; or Rio and Rio- are both fluorine; or Rio and Ric are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the Rio and Rio- atoms bound to the carbon atom are independently C(H), N, NH, 0, S, SO, or S02; wherein said ring optionally contains up to 4 heteroatoms independently selected from N, NH, 0, S, SO, and S02; wherein any atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; and wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, and a (C3-C10) heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; or
R9 and Rio are optionally taken together with the ring atoms to which they are bound to form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system up to 3 heteroatoms independently selected from N, NH, 0, S, SO, or S02; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; or
Rio and Rn are optionally taken together with the ring atoms to which they are bound to form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, or S02; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
R9 and Rii are optionally taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic or heterocyclic ring system containing up to 10 atoms; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; wherein each heteroatom in the heterocyclic ring system is selected from the group consisting of N, NH, 0, S, SO, or S02; Ri and R3 are each independently: (C1-C12 ) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-CIO) -cycloalkyl- or -cycloalkenyl] - (C1-C12) - aliphatic-,
(C6-C10) -aryl- (C1-C12) aliphatic-, or (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 3 aliphatic carbon atoms in each of Ri and R3 are optionally replaced by a heteroatom selected from O, N, NH, S, SO, or S0 in a chemically stable arrangement; wherein each of Ri and R3 is independently and optionally substituted with up to 3 substituents independently selected from J; R2, ,R4, and R are each independently: hydrogen- , (C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- (C1-C12) -aliphatic-, • or (C6-C10) -aryl- (C1-C12 ) -aliphatic- ; wherein up to two aliphatic carbon atoms in each of R2, R4, and R7 are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, and S0 in a chemically stable arrangement; wherein each of R2, R4, and R7 is optionally substituted with up to 3 substituents independently selected from J; R5 and R5. are each independently hydrogen or (C1-C12)- aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R5 is optionally substituted with sulfhydryl or hydroxy; or R5 is Ph or -CH2Ph and Rs- is H, wherein said Ph or -CH2Ph group is optionally substituted with up to 3 substituents independently selected from J; or
R5 and R5. together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, 0, SO, and S02; wherein said ring is optionally substituted with up to 2 substituents selected independently from J;
W is :
Figure imgf000021_0001
Figure imgf000021_0002
Figure imgf000022_0001
Figure imgf000022_0002
wherein m is 0 or 1; wherein each Re is independently: hydrogen-, (C1-C12) -aliphatic-, (C6-Cl0)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10) -cycloalkyl- or cycloalkenyl-, [ (C3-C10) -cycloalkyl- or cycloalkenyl] - (C1-C12) - aliphatic-,
(C3-C10) -heterocyclyl-,
(C3-C10) -heterocyclyl- (C1-C12 ) -aliphatic- , (C5-C10) -heteroaryl- , or (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 3 aliphatic carbon atoms in each R6 is optionally replaced by a heteroatom s'elected from 0, NH, S, SO, or SO2 in a chemically stable arrangement; wherein Re is optionally substituted with up to 3 J substituents; or two Re groups, together with the nitrogen atom to which they are bound, optionally form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, and S02, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, or a (C3-C10) heterocyclyl, wherein any ring has up to 3 substituents selected independently from J; wherein each R8 is independently -OR'; or the R8 groups together with the boron atom, is a (C3-C10)- membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N, NR' , 0, SO, and S02;
V is -C(0)-, -C(S)-,! -S(O)-, or -S(0)2-;
A is hydrogen or -C (Ri2 ) (Rι2< ) -T-R13 ;
T is oxygen or a bond;
R12 and R12' are each independently: hydrogen- , or (C1-C6 ) -aliphatic- ; wherein up to two aliphatic carbon atoms in each of R12 and Ri2< are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, and S0 in a chemically stable arrangement; or
R12 is absent and Ri2< is =0; ,
R13 is -C(0)R', -P(0)(OR')2, -S03R', -R', or -R19;
R19 is: hydrogen,
(C1-C12 ) -aliphatic- ,
(C6-C10 ) -aryl- (C1-C12 ) aliphatic- , or (C5-C10 ) -heteroaryl- (C1-C12 ) -aliphatic- ; wherein up to 3 aliphatic carbon atoms in each Rig are optionally replaced by a heteroatom selected from 0, NRig, S, SO, or S0 in a chemically stable arrangement ; wherein up to 3 aliphatic carbon atoms in each Ri9 are optionally replaced with -C(0)-; wherein Ri9 is optionally substituted with up to 3 J substituents ; wherein any NR19, taken together with the nitrogen and a carbon adjacent to the nitrogen, optionally forms a 5- to 7-membered ring system, wherein said ring system optionally contains up to three additional heteroatoms selected from 0, N, NH, S, SO, and S02 in a chemically stable arrangement; Ri4 and R5 are independently halogen, -OR', -OC (O)N(R' ) 2, -N02, -CN, -CF3, -0CF3, -R', 1,2-methylenedioxy, 1,2- ethylenedioxy, -N(R')2, -SR' , -SOR' , -S02R', -S02N(R')2, -SO3R', -C(0)R\ -C(0)C(0)R', -C(0)CH2C(0)R' , -C(S)R', -C(0)OR', -0C(0)R', -C(0)N(R')2, -OC (O)N(R' ) 2, -C(S)N(R')2, or -(CH2)o-2NHC(0)R' ; Ri6 is R', -C(0)R', -P(0)(0R')2, or -S03R'; U is 0, N, or a bond; and
Ris and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the Rι8 and Ris- atoms bound to the carbon atom are independently 0 or N; wherein ;said ring optionally contains up to 1 additional heteroatom selected from N, NH, 0, S, SO, and S02; wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, and a (C3-CIO) heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; provided that when Rι8 and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system, then Rι6 is R' ; or
Rι8< is =0, =CH2, =N(R')/ or =N(0R' ) and Ri8 is absent, provided that when Rι8 is absent and Ris- is =CH2, then U is oxygen; and provided that when Rι8 is absent and Ris- is =0, =N(R') or =N(0R' ) , then U is a bond and Rι6 is R' .
Definitions
[0014] The term "aryl" as used herein means a monocyclic or bicyclic carbocyclic aromatic ring system. Phenyl is an example of a monocyclic aromatic ring system. Bicyclic aromatic ring systems include systems wherein both rings are aromatic, e.g., naphthyl, and systems wherein only one of the two rings is aromatic, e.g., tetralin. It is understood that as used herein, the term " (C6-C10) -aryl-" includes any one of a C6, C7, C8, C9, and CIO monocyclic or bicyclic carbocyclic aromatic ring.
[0015] The term "heterocyclyl" as used herein means a monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from 0, N, NH, S, SO, and S02 in a chemically stable arrangement. In a bicyclic non-aromatic ring system embodiment of "heterocyclyl" one or both rings may contain said heteroatom or heteroatom groups. It is understood that as used herein, the term "(C5-C10)- heterocyclyl-" includes any one of a C5, C6, C7, C8, C9, and CIO monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from 0, N, NH, and S in a chemically stable arrangement .
[0016] The term "heteroaryl" as used herein means a monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from 0, N, NH, and S in a chemically stable arrangement. In such a bicyclic aromatic ring system embodiment of "heteroaryl" : - one or both rings may be aromatic; and
- one or both rings may contain said heteroatom or heteroatom groups. It is understood that as used herein, the term " (C5-C10) -heteroaryl- " includes any one of a C5, C6, C7, C8, C9, and CIO monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from 0, N, NH, and S in a ; chemically stable arrangement.
[0017] The term "aliphatic" as used herein means a straight chained or branched alkyl, alkenyl or alkynyl. It is understood that as used herein, the term "(C1-C12)- aliphatic-" includes any one of a Cl, C2 , C3 , C4, C5, C6, C7, C8, C9, CIO, Cll, and C12 straight or branched alkyl chain of carbon atoms. It is also understood that alkenyl or alkynyl embodiments need at least two carbon atoms in the aliphatic chain. The term "cycloalkyl or cycloalkenyl" refers to a monocyclic or fused or bridged bicyclic carbocyclic ring system that is not aromatic. Cycloalkenyl rings have one or more units of unsaturation. It is also understood that as used herein, the term " (C3-C10) -cycloalkyl- or -cycloalkenyl-" includes any one of a C3 , C4, C5, C6, C7, C8, C9, and CIO monocyclic or fused or bridged bicyclic carbocyclic ring. Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, nornbornyl, adamantyl and decalin-yl .
[0018] The phrase "chemically stable arrangement" as used herein refers to a compound structure that renders the compound sufficiently stable to allow manufacture and administration to a mammal by methods known in the art. Typically, such compounds are stable at a temperature of 40°C or less, in the absence of moisture or other chemically reactive condition, for at least a week.
Preferred Embodiments
[0019] According to an embodiment of compounds of formula I, V is -C(O)-.
[0020] According to another embodiment, the present invention provides a compound; of formula IA:
Figure imgf000027_0001
IA wherein:
Ri, R2, R3, R4, R5 s' / R7; R9/ R9' Rio/ Rio- f Rii Rii' 1 i4 Ri5/ i6; i8 i8' A, U, and W are as defined in any of the embodiments herein.
[0021] According to another embodiment of compounds of formula I,
A is -C(Rι2) (R12 -T-R13;
R12 and R12' are both hydrogen;
T is oxygen;
R13 is -C(0)R', -P(0) (OR')2, -SO3R', or -R';
R14 and R15 are both -R* ;
Ris- is =0 and Ri8 is absent;
U is a bond; and
Ri6 is R', wherein R' is selected from: (C1-C12 ) -aliphatic- , (C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12) - aliphatic-; wherein up to 5 atoms in R1 are optionally and independently substituted with J. [0022] According to another embodiment of compounds of formula I,
Ri3 is -C(0)R', -P(0)(OR')2, or -R';
Ri4 and Ri5 are both -R1 and R' is (C1-C12) -aliphatic-; and Ri6 is R' , wherein R' is (C1-C12 ) -aliphatic- . [0023] \ According to another embodiment, the present invention provides a compound of formula IB:
Figure imgf000028_0001
IB wherein:
I
R ' , Ri , R2 , R3 , R4 b , R ' i ^7 ; R9 R9 ' f lO , RlO ' Rll / Rii', R13, and W are as defined in any of the embodiments herein.
[0024] According to an embodiment of compounds of formula IB, Rι6 is -R' wherein R' is preferably methyl; Ri4 and R15 are both -R' and R' is preferably methyl; R13 is -C(0)R' or -P(O) (0R')2, wherein R' is as defined in any of the embodiments herein; and Ri, R2, R3, R4, R5, Rs-, R7, Rg, R , Rio, Rio Rii Rii-/ and W are as defined in any of the embodiments herein. [0025] According to another embodiment of compounds of formula I,
A is -C(R12) (Ri2-)-T-Rι3; R12 is hydrogen and Rι2- is (C1-C6) -aliphatic-; wherein up to two aliphatic carbon atoms in Ri2' are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, and SO in a chemically stable arrangement; T is oxygen;
R13 is -C(0)R', -P(0)(OR')2, -SO3R' , or -R1 ; Rι and Ri5 are both -R' ; Ris- is =0 and Rι8 is absent; U is a bond; and
Ri6 is R', wherein R' is selected from: (C1-C12 ) -aliphatic- ,
(C3-CIO) -cycloalkyl- or -cycloalkenyl-, [ (C3-CIO) -cycloalkyl or -cycloalkenyl] - (C1-C12 ) - aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J. [0026] According to another embodiment of compounds of formula I,
R12' is (C1-C6) -aliphatic-; R13 is -C(0)R', -P(0)(OR')2, or -R' ;
,Ri4 and Rι5 are both -R ' and R ' is (C1-C12 ) -aliphatic- ; Ri6 is R ' , wherein R ' is (C1-C12 ) -aliphatic- . [0027] According to another embodiment , the present invention provides a compound of formula IC :
Figure imgf000029_0001
IC wherein : R\ Ri, R2, R3, R , Rs, Rs-, R7, Rg, Rg-, Rio, Ric, R11, Rii', R12', R13, and W are as defined in any of the embodiments herein.
[0028] According to an embodiment of compounds of formula IC, Riε is -R1 wherein R' is preferably methyl; Ri4 and R15 are both -R' and R' is preferably methyl; R13 is -C(0)R' or -P(O) (OR') 2, wherein R' is as defined in any of the embodiments herein; Ri2' is methyl and R1# R2, R3, R4, R5, R5', R7, R9, Rg-, Rio, Rio' , R11, Rii-, and W are as defined in any of the embodiments herein.
[0029] According to another embodiment of compounds of formula I,
A is -C(Rι2) (R12 -T-R13;
R12 is absent and R12' is =0;
T is oxygen or a bond;
R13 is -Rig;
R14 and R15 are both -R ' ;
Ris- is =0 and Ri8 is absent ;
U is a bond; and
Ri6 is R', wherein R' is selected from:
(C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl-,
[ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12 ) - aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J. [0030] According to another embodiment, the present invention provides a compound of formula ID:
Figure imgf000031_0001
ID wherein :
R' , Ri, R2, R3, R4, R5, Rs-, R7, R9, Rg', Rio, Rio-, Rιι, Rii', R12', Rig, T, and W are as defined in any of the embodiments herein.
[0031] According to an embodiment of compounds of formula ID, Rx, R2, R3, R4, R5, R5', R7, Rg, R9', Rio, Ric, R11, Rii', and W are as defined in any of the embodiments herein;
T is a bond;
Ri6 is -R' wherein R' is preferably methyl; R14 and R15 are both -R1 and R' is preferably methyl; R13 is Rig, wherein R9 is as defined in any of the embodiments herein.
[0032] According to another embodiment of compounds of formula ID, Rig is:
(C1-C12) -aliphatic-, wherein 1 to 2 aliphatic carbon atoms in each Rig are optionally replaced by a heteroatom selected from 0 or NR19, in a chemically stable arrangement; wherein 1 to 2 aliphatic carbon atoms in each R19 is optionally replaced with -C(0)-; wherein R19 is optionally substituted with up to 3 J substituents . [0033] According to a preferred embodiment of compounds of formula ID, R19 is: (C3-C6) -aliphatic-, wherein 1 to 2 aliphatic carbon atoms in each Ri are optionally replaced by a heteroatom selected from 0 or NRig, in a chemically stable arrangement; wherein 1 to 2 aliphatic carbon atoms in each Rig is optionally replaced with -C(O)-; wherein Rι9 is optionally substituted with up to 3 J substituents . [0034] According to another embodiment of compounds of formula I,
Ris- is =CH2, and Rι8 is absent; U is oxygen; ?
Rie is R', -C(0)R\ -P(0)(OR')2, or -S03R' ; Ri4 and Ri5 are both -R' ; and A is hydrogen.
[0035] According to another embodiment of compounds of formula I,
Ris is R\ -C(0)R\ or -P(0) (OR' )2;
Ri4 and Ri5 are both -R' and R' is (C1-C12 ) -aliphatic- . [0036] According to another embodiment, the present invention provides a compound of formula IE:
Figure imgf000032_0001
IE wherein:
R', Ri, R2, R3, R4, Rs, Rs-, R7, Rg, Rg', Rio, Rιo<, Rii, Rii', Rie, and W are as defined in any of the embodiments herein. [0037] According to an embodiment of compounds of formula IE, Rι6 is -C(0)R', -P(O) (OR')2,; Ri4 and Ri5 are both -R' and R' is preferably methyl; A is hydrogen; and Ri, R2, R3, R4, Rs, R5', R7, Rg, Rg-, Rio, Rio-, R11, Rii', and W are as defined in any of the embodiments herein.
[0038] According to an embodiment of compounds of formula I, Ris- is =N(R') or =N(OR') and Ri8 is absent; U is a bond; Rie is R' ;
R14 and R15 are both -R' ; and A is hydrogen.
[0039] In another embodiment of compounds of formula I, U is -NR'-.
[0040] According to another embodiment of compounds of formula I, R14 and R15 are both -R' and R' is
(C1-C12 ) -aliphatic- .
[0041] According to another embodiment, the present invention provides a compound of formula IF:
Figure imgf000033_0001
IF wherein: ;
R' , Ri, R2, R3, R4, Rs, s-, R7, Rg, Rg', Rio, Rio-, R11, Rii-, Ri6, Ri8', and W are as defined in any of the embodiments herein.
[0042] According to an embodiment of compounds of formula IF, Rx8' is =N(R') or =N(OR') and Rι8 is absent; Rι6 is R' ; R14 and R15 are both -R' and R' is preferably methyl; A is hydrogen; and Ri, R2, R3, R4, R5, R5', R7, Rg,
Rg-, Rio, Rio-, R11, Rii', and W are as defined in any of the embodiments herein. [0043] According to another embodiment of compounds of formula I,
Ris and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the R18 and Rι8< atoms bound to the carbon atom are independently 0 or N; wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, 0, S, SO, and SO2; wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, and a (C3-C10) heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J;
U is a bond;
Ri6 is R' ;
R14 and R15 are both -R' ; and
A is hydrogen.
[0044] According to another embodiment of compounds of formula I, the Ris and Ri8- atoms bound to the carbon atom are 0 and the ring formed when Ri8 and Rι8- are optionally taken together with the carbon atom to which they are bound optionally contains up to 1 additional oxygen atom and is optionally substituted with up to 2 J substituents.
[0045] According to another embodiment, the present invention provides a compound of formula IG:
Figure imgf000035_0001
IG wherein : r is 0, 1, or 2, Ri6 is R' , R' , Ri, R , R3, R4, Rs, R5', R7, Rg, Rg-, Rio, Rio-, R11, Rii-, and W are as defined in any of the embodiments herein. •
[0046] According to an embodiment of compounds of formula IG, the Rι8 and Ris- atoms bound to the carbon atom are 0; the ring formed when Ri8 and Rι8' are optionally taken together with the carbon atom to which they are bound is a 5- or 6-membered ring system optionally substituted with up to 2 J substituents; Ri6 is R' ; R14 and R15 are both -R' and R' is preferably methyl; A is hydrogen; and Rx, R2, R3, R4, R5, Rs-, R7, Rg, Rg-, Rio, Rio- , R11, Rii-, and W are as defined in any of the embodiments herei .
[0047] According to another embodiment, this invention does not include compounds wherein T is 3-acetyl-4, 5- dimethyl-lH-pyrrole (e.g., see compounds 63-64 at page 95, and compounds 66-67 at page 96 of WO 03/087092) . [0048] According to another embodiment, this invention does not include compounds wherein: V is -C(O)-, -C(S)-, -S(O)-, or -S(0)2-; and radical T is:
Figure imgf000036_0001
wherein :
R20 is -H, -S(0)R°, -S(0)2R°, -C(0)R°, -C(0)OR°, -C(0)N(R°)2, -N(R°)C(0)R°, j-N ( COR° ) COR° , -S02N(R°)2, -SO3R0, -C(0)C(0)R°, -C(0)CH2C(0)R°, -C(S)R°, -C(S)N(R°)2, -(CH2)0- 2NHC(0)R°, -N(R°)N(R°)COR°, -N(R°)N (R°) C (0) OR°, -N(R°)N(Ro)C0N(Ro)2, -N(R°)S02R°, -N (R°) S02N(R°) , -N(R°)C(0)OR°, -N(R°)C(0)R°', -N (R°) C (S) R°, -N (R°) C (0)N(R°) 2, -N(R0)C(S)N(R°)2, -N(C0R°)C0R°, -N(0R°)R°, -C (=NH) N (R°) 2, -C(0)N(0R°)R°, -C(=N0R°)R°, -OP (0) (OR°) 2, -P(0) (R°)2, -P(O) (0R°)2, or -P(O) (H) (OR°) ;
R21 and R22 are independently halogen, -0R°, -0C(0)N(R°)2, -N02, -CN, -CF3, -OCF3, -R°, oxo, 1,2- methylenedioxy, 1, 2-ethylenedioxy, -N(R°)2, -SR°, -S0R°, -S02R°, -S02N(R°)2, -S03R°, -C(0)R°, -C(0)C(0)R°, -C(0)CH2C(0)R°, -C(S)R°, -C(0)0R°, -OC(0)R°, -C(0)N(R°)2/ -OC(0)N(R°)2, -C(S)N(R°)2, -(CH2)o-2NHC(0)R°;
Z2 is =0, =NR°, =N0R°, or =CH2;
R23 is -0R°, -CF3, -OCF3, -R°, -N(R°)2, -C(0)R°, or -N(R°)C0R°; two R° groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or non- aromatic ring having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, or S02, wherein the ring is optionally fused to a (C6-C10) aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or a (C3-C10) heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J3; or each R° is independently selected from: hydrogen- , (C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl or -cycloalkenyl-, [ (C3-C10) -cycloalkyl or -cycloalkenyl] - (Cl- C12 ) -aliphatic- ,
(Cδ-ClO)-aryl-, (C6-C10 ) -aryl- (C1-C12 ) aliphatic- ,
* (C3-CIO) -heterocyclyl-,
(C6-C10 ) -heterocyclyl- (C1-C12 ) aliphatic- , (C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-, wherein R° has up to 3 substituents selected independently from J3; and
J3 is halogen, -OR°, -OC (0)N(R°) 2, -N02, -CN, -CF3, -OCF , -R°, oxo, thioxo, 1, 2-methylenedioxy, -N(R°)2, -SR°, -SOR°, -S02R°, -S02N(R0)2, -S03R°, -C(0)R°, -C(0)C(0)R°, -C(0)CH2C(0)R°, -C(S)R°, -C(0)OR°, -0C(0)R°, -C(0)N(R°)2, -0C(0)N(R°)2, -C(S)N(R°)2, -(CH2)o-2NHC(0)R°, -N(R°)N(R°)C0R°, -N(R°)N(R°)C(0)0R°, -N (R°) N (R°) C0N(R°) 2, -N(R°)S02R°, -N(R°)S02N(R°)2, -N(R°) C (0) 0R°, -N (R°) C (0) R°, -N(R°)C(S)R°, -N(R°)C(0)N(R°)2, -N (R°) C (S)N(R°) 2, -N(C0R°)C0R°, -N(OR°)R°, -CN, -C (= H) N (R°) 2 , -C (0) N (0R°) R°, -C(=N0R°)R°, -0P(0) (0R°)2, -P(0)(R°)2, -P(0)(OR°) , or -P(O) (H) (OR°) (e.g., see compounds of formula II at page 22 of WO 03/087092) .
[0049] According to another embodiment of compounds of formula I, when Ris- is =0, Ris is absent, U is a bond, and Rie is R', then A is -C(Rι2) (Rι2- ) -T-Ri3.
[0050] According to another embodiment of compounds of formula I, when A is hydrogen, Rι6 is R', -C(0)R', -P(O) (OR') 2, or -SO3R' ; U is 0, or N, or a bond; and
Ris and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the Rι8 and Ris- atoms bound to the carbon atom are independently 0 or N; wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, 0, S, SO, and S02; wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, and a (C3-CIO) heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; provided that when Ri8 and Rig- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system, then Ri6 is R'; or Ris- is =0, =CH2, =N(R'), or =N(0R') and Ri8 is absent, provided that when Ri8 is absent and Ris- is =CH2, then U is oxygen; and provided that when Rι8 is absent and Ris- is =0, =N(R') or =N(0R' ) , then U is a bond and Rie is R' . [0051] According to another embodiment of compounds of formula I, the
Figure imgf000038_0001
radical is
Figure imgf000039_0001
wherein: n is 0, 1, or 2;
Z and Z' are independently C(H), N, NH, 0, or S;
R9, Rg-, Rii, and Ru- are as defined in any of the embodiments herein; and the spirocyclic ring containing Z and Z ' is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein. [0052] According to another embodiment the
Figure imgf000039_0002
radical is
Figure imgf000039_0003
wherein :
Rii and Ru- are both H; n is 0 , 1 , or 2 ;
Rg and R9- are as defined in any of the embodiments herein; and the spirocyclic ring containing Z and Z' is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein. [0053] According to a preferred embodiment, the radical is
Figure imgf000040_0001
wherein : n is 0 or 1. [0054] According to another embodiment, the present invention provides a compound of formula IH:
Figure imgf000040_0002
IH wherein :
Ri, R2, R3, R4, Rs, R5', R7, Rg, Rg-, R11, Rii', R14, Ris, Rie, Ris, Ris-, n, V, A, U, Z, Z' and W are as defined in any of the embodiments herein. [0055] According to another embodiment the
radical is
Figure imgf000040_0003
wherein :
Z and Z' are independently C(H), N, NH, 0, or S; Rg, Rg-, Ri , and Ru- are as defined in any of the embodiments herein; and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
[0056] According to another embodiment, the present invention provides a compound of formula IJ:
Figure imgf000041_0001
IJ wherein :
Ri, R2, R3, R4, R5, R5', R7, Rg, Rg-, Ru, Rn-, R14, Ris,
Rie, Ris, Ri8', V, A, U, Z, Z' and W are as defined in any of the embodiments herein; and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
[0057] According to a preferred embodiment for compounds of formula IJ, Z and Z' are S, Rg and Rg- are H, R , R2, R3, R , R5, R5<, R7, Ru, Ru-, R14, R15, Rie, Ris, Ris-,
V, A, U, and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein. [0058] According to another embodiment of compounds of formula I, the radical is :
Figure imgf000042_0001
wherein :
R9, Rg-, Ru, and Ru- are H. [0059] In a preferred embodiment, the
RI FXF.R9'
RIIVN-( Rg
' J^ radical is
Figure imgf000042_0002
wherein :
Rg, Rg-, Ru, and Ru- are H. [0060] According to another embodiment, the present invention provides a compound of formula IK:
Figure imgf000042_0003
IK wherein : Ri, R2, R3, R4, Rs, s-, R?, Rg, R9', Rii, Rii', Ri4, Ris, Ri6, Ris, Ris-, V, A, U, and W are as defined in any of the embodiments herein .
[0061] According to another embodiment of compounds of formula I, in the
Figure imgf000043_0001
radical Rg, Rio, Rie Ru, and Rπ- are H; and Rg- is:
(C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-; wherein up to three aliphatic carbon atoms in R9» may be replaced by O, N, NH, S, SO, or S02; wherein R9 , is independently and optionally substituted with up to 3 substituents independently selected from J. [0062] According to another embodiment of compounds of formula I, the
Figure imgf000043_0002
radical is
Figure imgf000043_0003
[0063] According to another embodiment of compounds of formula I, in the
Figure imgf000043_0004
radical
R9, R9 ,, Rio, Ru, and Ru- are H; and
Rio- is: (C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, (C6-C10)-aryl-, wherein any ring is optionally fused to a (C6-Cl0)aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, or (C3-CIO) heterocyclyl; wherein up to 3 aliphatic carbon atoms in Rio- may be replaced by a heteroatom selected from 0, NH, S, SO, or S02 in a chemically stable arrangement; wherein Rio-, is independently and optionally substituted with up to 3 substituents independently selected from J. [0064] According to another embodiment of compounds of formula I, the I
Figure imgf000044_0001
radical is
Figure imgf000044_0002
[0065] According to yet another embodiment of compounds of formula I, in the
Figure imgf000044_0003
radical
Rg , R9< , Rio , Rio- , and Ru are H; and
Ru- is: (C1-C12 ) -aliphatic- , (C3-C10) -cycloalkyl- or -cycloalkenyl-, (Cδ-ClO)-aryl-, wherein any ring is optionally fused to a (C6-Cl0)aryl, (C5-C10)heteroaryl, (C3-C10) cycloalkyl, or (C3-C10) heterocyclyl; wherein up to 3 aliphatic carbon atoms in Ru- may be replaced by a heteroatom selected from 0, NH, S, SO, or S02 in a chemically stable arrangement; wherein Ru-, is independently and optionally substituted with up to 3 substituents independently selected from J. [0066] According to another embodiment of compounds of formula I, the
Figure imgf000045_0001
radical is:
Figure imgf000045_0002
[0067] According to another embodiment of compounds of formula I, in the
Figure imgf000045_0003
radical
Rg, Rio, Ru, and Ru- are H; and R9- and Rio- are: '
(C1-C12) -aliphatic-, (C3-C10) -cycloalkyl- or -cycloalkenyl-, wherein up to 3 aliphatic carbon atoms in R9 , and Rio- may be replaced by a heteroatom selected from 0, NH, S, SO, or SO2 in a chemically stable arrangement; wherein R- and Rio- are independently and optionally substituted with up to 3 substituents independently selected from J. [0068] According to another embodiment of compounds of formula I, the
Figure imgf000045_0004
radical is :
Figure imgf000046_0001
[0069] According to another embodiment of compounds of formula I, in the
Figure imgf000046_0002
radical Rg, Rg-, Rio-, Ru, and Ru- are H; and R' is selected from: (C6-C10)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10) -heterocyclyl-, (C3-C10) -heterocyclyl- (C1-C12 ) aliphatic-,
(C5-C10) -heteroaryl- , and (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J. [0070] According to another embodiment of compounds of formula I, the
Figure imgf000046_0003
radical is
Figure imgf000046_0004
Figure imgf000047_0001
wherein up to 5 atoms in R' are optionally and independently substituted with J.
[0071] According to another embodiment of compounds of formula I, the
radical is
Figure imgf000047_0002
Figure imgf000047_0003
wherein up to 5 atoms in R1 are optionally and independently substituted with J. [0072] According to yet another embodiment of compounds of formula I, in the
Figure imgf000048_0001
radical Rg, Rg-, Rie, Ru, and Ru- are H; and R' is selected from: (C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10 ) -heterocyclyl- (C1-C12) aliphatic- and (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J. [0073] According to a preferred embodiment of compounds of formula I, the
Figure imgf000048_0002
wherein up to 5 atoms in R' are optionally and independently substituted with J.
[0074] According to another embodiment, the present invention provides a compound of formula IL:
Figure imgf000048_0003
IL wherein:
R\ Ri, R2, R3, R4, Rs, Rs- , Rv, Rg, Rg-, Rn, Rii', Ri4, Ris, Ri6, Ris, Ris-, V, A, U, and W are as defined in any of the embodiments herein.
[0075] According to another embodiment of compounds of formula I, the
radical is :
Figure imgf000049_0001
wherein; ring A is a 5- to 6-membered aromatic or a 3- to 7-membered non-aromatic ring system having up to 3 heteroatoms independently selected from N, NH, O, SO, or S02; wherein said ring A is optionally fused to a (C6- Cl0)aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, or (C3- C10) heterocyclyl; > wherein any ring has up to 3 substituents selected independently from J; and
Rg, R,, Rie, and Ru- are as defined in any of the embodiments herein.
[0076] According to another embodiment of compounds of formula I , the
Figure imgf000049_0002
radical is
Figure imgf000049_0003
Figure imgf000050_0001
[0077] According to another embodiment of compounds of formula I, the
Figure imgf000050_0002
radical is :
Figure imgf000050_0003
[0078] According to another embodiment of compounds of formula I, the
Figure imgf000050_0004
[0079] According to 'a preferred embodiment, the
s
Figure imgf000050_0005
[0080] According to another embodiment, the present invention provides a compound of formula IM:
Figure imgf000051_0001
IM wherein :
Ri, R , R3, 4, Rs, R5', R7, Rg, Rg', Rio', Rii', R14, R15, Rie, Ris, is-, V, A, U, W, and ring A are as defined in any of the embodiments herein.
[0081] According to another embodiment of compounds of formula I, the
radical is :
Figure imgf000051_0002
wherein; ring A is a 5- to 6-membered aromatic or a 3- to 7-membered non-aromatic ring system having up to 3 heteroatoms independently selected from N, NH, 0, SO, or S02 ; wherein said ring A is optionally fused to a (C6- Cl0)aryl, (C5-C10) eteroaryl, (C3-CIO) cycloalkyl, or (C3- Cl0 ) heterocyclyl ; wherein any ring has up to 3 substituents selected independently from J; and
R9', Rio', Ru, and Ru- are as defined in any of the embodiments herein.
[0082] According to another embodiment of compounds of formula I, the
Figure imgf000052_0001
radical is
Figure imgf000052_0002
[0083] According to yet another embodiment of compounds of formula I, the
Figure imgf000052_0003
radical is :
Figure imgf000052_0004
[0084] According to another embodiment, the present invention provides a compound of formula IN:
Figure imgf000053_0001
IN wherein:
Ri, R2, R3, R4, Rs, R5', R7, Rg', Rio, Rii', R11, R14, R15, Ri6, Ris, Ri8', V, A, U, W, and ring A are as defined in any of the embodiments herein.
[0085] According to another embodiment of compounds of formula I , the
radical is
Figure imgf000053_0002
wherein: 1 ring B forms a 3- to a 20-membered carbocyclic or heterocyclic ring system; wherein each ring B is either aromatic or nonaromatic; wherein each heteroatom in the heterocyclic ring system is N, NH, O, SO, or S02; wherein ring B is optionally fused to a (C6- Cl0)aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or (C3- Cl0) heterocyclyl; wherein each ring has up to 3 substituents selected independently from J; and
Rg- and Ru- are as defined in any of the embodiments herein. [0086] According to another embodiment, the
Figure imgf000054_0001
radical is
Figure imgf000054_0002
[0087] According to yet another embodiment, the present invention provides a compound of formula 10:
Figure imgf000054_0003
10 wherein:
Ri, R , R3, R4, Rs, Rs-, R7, Rg', Rii', Ri4, Ris, Ri6, Ris, Ris-, V, A, U, W, and ring B are as defined in any of the embodiments herein .
[0088] According to another embodiment, W in compounds of formula I is :
Figure imgf000054_0004
wherein in the W, the NRεRβ is selected from -NH- (C1-C6 aliphatic), -NH-(C3-C6 cycloalkyl), -NH-CH (CH3) -aryl, or -NH-CH(CH3) -heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with up to 3 halogens . [0089] According to another embodiment in compounds of formula I, the RgRε in the W radical is:
Figure imgf000055_0001
[0090] According to another embodiment in compounds of formula I, the R6R6 in the W radical is:
Figure imgf000055_0002
[0091] More preferably, in the W, the NRεRβ is
Figure imgf000055_0003
[0092] Even more preferably, in the W, the NR6R6 is
H -
Figure imgf000055_0004
[0093] According to another embodiment in compounds of formula I, the NRβRβ in the W radical is:
Figure imgf000056_0001
[0094] According to another embodiment in compounds of formula I, the NR6R6 in the W radical is:
[0095] In yet another embodiment, in the W, the R6R6
Figure imgf000056_0003
[0096] According to another embodiment, the present invention provides a compound of formula IP:
Figure imgf000056_0004
IP wherein :
Ri, R , R3, R4, Rs, Rs-, Rδ, R7, Rg, Rg-, Rio, Rie, R11, Rii', Ri4, Ris, Ri6, Ris, Ri8', V, A, and U are as defined in any of the embodiments herein.
[0097] According to another embodiment W in compounds of formula I is :
B
R 8; wherein R8 is as defined above.
[0098] According to another embodiment for W in compounds of formula I, each R8 together with the boron atom, is a (C5-CIO) -membered heterocyclic ring having no additional heteroatoms other than the boron and the two oxygen atoms. Preferred groups are selected from:
Figure imgf000057_0001
wherein R' is, preferably, (C1-C6) -aliphatic and is, more preferably, methyl.
[0099] According to another embodiment in compounds of formula I, R5> is hydrogen and R5 is:
Figure imgf000057_0002
[0100] According to a preferred embodiment in compounds of formula I, R5> is hydrogen and R5 is:
Figure imgf000058_0001
[0101] According to another embodiment, the present invention provides a compound of formula IQ :
Figure imgf000058_0002
IQ wherein: Ri, R2, R3, R4, Re, R7, Rg, Rg', Rio, Rie, R11, Rii', Ri4, Ris, Ris, Ri8, Ris-, V, A, and U are as defined in any of the embodiments herein .
[0102] According to a preferred embodiment for compounds of formula IQ, Ri, R2, R3, R4, R7, R9, R9', Rio, Rio', R11, Rii', R14, Ris, Rie, Ris, Ris-, V, A, and U are as defined in any of the embodiments herein, and NRεRε is:
Figure imgf000058_0003
[0103] Ac 'cording to another embodiment in compounds of formula I, R5. and R5 is:
Figure imgf000058_0004
[0104] According to another embodiment for compounds of formula I, R2, R4, and R7, are each independently H, methyl , ethyl , or propyl . [0105] According to a preferred embodiment R2/ R4, and R7 are each H.
[0106] According to another embodiment, the present invention provides a compound of formula IR:
Figure imgf000059_0001
IR wherein :
. Ri, R2, R3, R4, Re, R7, R9, R9', Rio, Rio-, R11, Ru-, R14, R15, Rie, is, Ris-, V, A, and U are as defined in any of the embodiments herein.
[0107] According to a preferred embodiment for compounds of formula IR, Ri, R2, R3, R4, R7, Rg, Rg-, Rio, Rio-, R11, Rii', Ri4, Ris, Rie, Ris, Ris-, V, A, and U are as defined in any of the embodiments herein, and NRsRβ is:
Figure imgf000059_0002
[0108] According to another embodiment in compounds of formula I, R3 is :
Figure imgf000059_0003
[0109] According to a preferred embodiment in compounds of formula I, R3 is :
Figure imgf000060_0001
[0110] According to a more preferred embodiment in compounds of formula I, R3 is :
Figure imgf000060_0002
[0111] According to another embodiment, the present invention provides a compound of formula IS :
Figure imgf000060_0003
IS wherein :
Ri, R6, Rg, Rg-, Rio, Rio- , Ru, Ru-, Ri4, Ris, Ri6, Ris, Ris-, V, A, and U are as defined in any of the embodiments herein.
[0112] According to another embodiment in compounds of formula I, Ri is :
Figure imgf000060_0004
[0113] According to a preferred embodiment in compounds of formula I, Ri is:
Figure imgf000061_0001
[0114] More preferably, Ri is cyclohexyl .
[0115] According to another embodiment, the present invention provides a compound of formula IT:
Figure imgf000061_0002
IT wherein :
Rζ , Rg, Rg-, Rio, RlO', Rll, Rll', Rl4, Rl5, Rlδ, Rl8, Rl8', V, A, and U are as defined in any of the embodiments herein.
[011S] According to another embodiment for compounds of formula IT, R6, Rg, Rg-, Rio, Rio', Ru, Ru-, and R12 are as defined in any of the embodiments herein, and NR5R6 is: H ^ .
[0117] According to another embodiment for compounds of formulae I, and IA-IT, Ri4 and Rι5 are both -R' and R' is - (C1-C6 aliphatic) . More preferably, R14 and R15 are both methyl . [0118] The compounds of this invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be of the R or S configuration. [0119] Preferably, the compounds of this invention have the structure and stereochemistry depicted in formulae IA-IT.
[0120] Any of the preferred embodiments recited herein, including those embodiments in the above species, may define formula I individually or be combined to produce a preferred embodiment of this invention. [0121] The compounds of this invention contain, and may be modified to contain, appropriate functionalities to enhance selective biological properties compared to the corresponding parent compound. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system) , increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion. [0122] Without being bound by theory, we believe the compounds of this invention may enhance biological, properties by behaving as prodrugs .
[0123] Chemical modifications of a drug into a bio- or chemically-reversible prodrug can confer temporary aqueous solubility to the drug substance that allows absorption following oral administration. See generally, Liu, S.; Han, C; Wang, B. "Prodrug Derivatization as a Means to Enhance the Delivery of Peptide and Peptidomimetic Drugs" in Frontiers of Biotechnology and Pharmaceuticals, Ming Guo, ed, Science Press, New York, pp. 291-310 (2002) and Borchardt, R.T. and Wang, B. "Prodrug Strategies to Improve the Oral Absorption of Peptides and Peptide Mimetics" in Controlled Drug Delivery. Designing Technologies for the Future . Park. K. and Mrsny, R.J. Eds, American Chemical Society,
Washington, D.C., pp. 36-45 (2000)
[0124] Prodrug strategies which rely on intramolecular cyclization to liberate a drug substance and a lactam derivative have been described where the liberated drugs are alcohols, phenols, and primary and secondary amines.
For alcohols see, Saari et al . , J". Med. Chem. , 33, pp.
2590-2595 (1990). For phenols see, Saari et al . , J. Med.
Chem . , 33, pp. 97-101 (1990). For amines see, Borchardt et al., Pharm. Sci., 86, pp. 757-767 (1997).
[0125] Any of the preferred embodiments recited herein, including those embodiments in the above species, may define formula (I) individually or be combined to produce a preferred embodiment of this invention. [0126] Abbreviations which are used in the schemes, preparations and the examples that follow are:
THF : tetrahydrofuran
DMF : N,N, -dimethylformamide
EtOAc : ethyl acetate AcOH: acetic acid
NMM: N-methylmorpholine ,
NMP: N-meth lpyyrolidinone
EtOH: ethanol t-BuOH: tert-butanol Et20: diethyl ether
DMSO: dimethyl sulfoxide
DCCA: dichloroacetic acid
DIEA: diisopropylethylamine
MeCN: acetonitrile TFA: trifluoroacetic acid
DBU: 1, 8-diazabicyclo[5.4.0] undec-7-ene
DEAD: diethyl azodicarboxylate
HOBt : 1-hydroxybenzotriazole hydrate
HOAt : l-hydroxy-7-azabenzotriazole EDC : 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
Boc : tert-butyloxycarbonyl
Boc20: di-tert-butyldicarbonate Cbz : benzyloxycarbonyl
Cbz-Cl: benzyl chloroformate
Fmoc : 9-fluorenyl methyloxycarbonyl
SEM: silylethoxymethyl
TBAF : tetrabutylammonium fluoride Chg: cyclohexylglycine t-BG: tert-butylglycine mCBPA: 3-chloroperoxybenzoic acid
DAST: (diethylamino) sulfur trifluoride
TEMPO: 2 , 2, 6, 6-tetramethyl-l-piperidinyloxy, free radical PyBOP: tris (pyrrolidino)bromophosphonium hexafluorophosphate
TBTU or HATU: 2- (lH-benzotriazole-1-yl) -1, 1, 3 , 3- tetramethyluronium tetrafluoroborate
DMAP: 4-dimethylaminopyridine AIBN: 2 , 2 ' -azobisisobutyronitrile rt or , R : room temperature
ON overnight ND not determined MS mass spectrometry LC liquid chromatography
General Synthetic Methodology:
[0127] The compounds of this invention may be prepared in general by methods known to those skilled in the art. Advantageously, these compounds are conveniently synthesized from readily available starting materials. Schemes 1-17 below illustrate synthetic routes to the compounds of the present invention. [0128] As can be appreciated by the skilled artisan, the synthetic schemes shown are not intended to comprise a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized. Other equivalent schemes, which will be readily apparent to the ordinary skilled organic chemist, may alternatively be used to synthesize various portions of the molecule as illustrated by the general schemes below. Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds . Other equivalent schemes, which will be readily apparent to the ordinary skilled organic chemist, may alternatively be used to synthesize various portions of the molecule as illustrated by the general schemes below, and the preparative examples that follow.
Scheme 1 :
HC!
EtOAc
Figure imgf000065_0001
Figure imgf000065_0002
Figure imgf000066_0001
Figure imgf000066_0002
Figure imgf000066_0003
IA-1
[0129] Scheme 1 above provides a general route for the preparation of compounds of formula I and IA-1, wherein V is -C(O), W is -C(0)C(0) -N(R6)2, R2, R4, and R7 are H, and Ri, R3, R5, Rs-, Re, Rg, R9', Rio, Rιo<, R11, Rii', R12, R12', R14, Ris, Rie, Ris, Ris-, A, and U are as described in any of the embodiments herein. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediates 3, 5, 7, and 10. Additionally, it will be recognized that the commercially available Cbz protected amino acids represented by, for instance, Cbz-Ri-OH, may alternatively be substituted with the commercial t-Boc protected amino acids . Suitable deprotection conditions to remove the Boc protecting groups are known to those skilled in the art. Likewise the oxidation of intermediate 10 to compounds of formula IA-1 may be accomplished using other suitable conditions known to the skilled artisan. Intermediate 2 may be prepared according to the procedures described by Schoellkopf, et al., Justus Liebigs Alia . Chem . GE, pp. 183-202 (1976) and Stemple et al . , Organic Letters, 2(18), pp. 2769-2772 (2000) . Intermediate pyrrole acid 9 may be prepared according to the methods described in the schemes below starting from commercially available starting materials.
Scheme 2 :
Figure imgf000067_0001
Figure imgf000068_0001
[0130] Scheme 2 above provides a general route for the ■'preparation of compounds of formula I and IA-2 wherein V is -C(O), W is -C(0)C(0) -N(R6)2, Ris is absent and R18- is =0, U is a bond, A is -C(Rι ) (Ri2')-T-Rι3 wherein R12 is absent, Ri2' is =0, T is a bond and Ri3 is R19, R19 is a (Cl- C12 ) -aliphatic- with one carbon atom replaced by an NR19 substituent, Rig is hydrogen, x is preferably 2-4, R, R4, and R7 are H, and Rx , R3, R5, R5> , R6, R9, R9 ,, Rio, io-, R11, Ru-, R12, R12', R14, Ris, and Rig are as described in any of the embodiments herein.- The preparation of compounds of formula I and IA-2, wherein Ri3 is different than that depicted in scheme 2, may be accomplished in similar fashion by acylation of the pyrrole anion using other commercially available acid chlorides . As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate 1 . Likewise the oxidation of intermediate 14 may be accomplished using other suitable conditions known to the skilled artisan.
Scheme 3
Figure imgf000069_0001
Dess Martin periodinane
Figure imgf000069_0002
Figure imgf000069_0003
route for the preparation of compounds of formula I and IA-3 wherein V is -C(O), W is -C(0)C(0) -N(R6)2, Ris is absent and Ri8' is =0, U is a bond, A is -C(Rι2) (Rι2')-T-Rι3 wherein R12 is hydrogen, Ri2' is CH, T is oxygen and Rι3 is -C(0)R', R2, R4, and R7 are H, and R' , Ri# R3, R5, R5-, R6, R9, R9<, R0, Rie, R11, Rii', Ri2, R12', Ri4, R15, and Riε are as described in any of the embodiments herein. Condensation of the pyrrole 16 with paraformaldehyde is accomplished according to the procedures listed in PCT publication WO 97/41132. The preparation of compounds of formula I and IA-2, wherein R12 is hydrogen, Ri2< is (C2-C6) -aliphatic- may be accomplished in similar fashion by substituting the appropriate aldehyde for paraformaldehyde in the conversion of 16 to 17. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate 20. Likewise the oxidation of intermediate 20 may be accomplished using other suitable conditions known to the skilled artisan.
Scheme 4 : .?
Figure imgf000070_0001
Figure imgf000071_0001
[0132] Scheme 4 above provides a general route for the preparation of compounds of formula I and IA-4 and IA-5 wherein V is -C(O), W is -C (0) C (0) -N(R6) , Ris is absent and Ris- is =0, U is a bond, A is -C(Ri2) (Rι2')-T-Rι3 wherein R12 is hydrogen, Rι2- is CH, T is oxygen and Rι3 is -P(0)(0R')2, R' is benzyl (IA-4) or hydrogen (IA-5), R2, R4,' and R7 are H, and R' , Rx, R3, R5, Rs-, Re, R9, R9', Rio, Rie, R11, Ru-, Rι2, R12', R14, Ris, and Rie are as described in any of the embodiments herein. Pyrrole alcohol 17 (prepared by methods described above in scheme 3) is converted to chloride 18 with thionyl chloride followed by displacement with potassium dibenzyl phosphate to give phosphate ester 22 all according to the procedures listed in PCT publication WO 97/41132. Mild acid hydrolysis of the t-butyl ester followed by the coupling conditions and oxidation described in scheme 3 above gives compound IA- 4. Hydrogenolysis of dibenzyl ester IA-4 using standard palladium catalysis gives free phosphonooxy acid IA-5. The preparation of compounds of formula IA-4, wherein R' is other than benzyl may be accomplished in similar fashion by using the appropriate phosphate reagent for the conversion of 21 to 22. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate 24. Likewise the oxidation of intermediate 24 and the hydrogenolysis of IA-4 may be accomplished using other suitable conditions known to the skilled artisan.
Scheme 5
Figure imgf000072_0001
8, PyBOP,
NMM, CH2C12
Figure imgf000072_0002
Figure imgf000072_0003
30
Figure imgf000072_0004
IA-6 [0133] Scheme 5 above provides a general route for the preparation of compounds of formula I and IA-6 wherein V is -C(O), W is -C(0)C(0) -N(R6)2, Ris is absent and Ris- is =N(OR'), U is a bond, Ri6 is R', A is hydrogen, R, R4, and R7 are H, R' , Rl r R3, R5, R5,, R6, R9, R9', Rio, Rio-, R11,
Rii', R12, R12', Ri4, and R15, are as described in any of the embodiments herein. Pyrrole acid 25 (prepared by methods described above in scheme 3 and below in scheme 6) is esterfied to give SEM ester 26. Protection of the pyrrole nitrogen according to the procedure in J. Chem . Soc. Perkin Trans . 1, pp. 2181-2186 (1986) provides intermediate 27. Condensation with hydroxylamine (or alkylhydroxyl amine wherein Rι8 is absent and Ri8' is =N(OR')), accomplished according to the procedure in J. Org. Chem. , pp. 5917-5921 (1992), gives oxime 28. TBAF deprotection of both silyl based protecting groups according to the procedure described in J. Chem . Soc . Perkin Trans . (1) , pp. 2181-2186 (1986) , gives pyrrole oxime acid 29. Final coupling and oxidation are accomplished according to the procedures listed above in schemes 1, 3, and 5. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate 30. Likewise the oxidation of intermediate 30- to IA-6 may be accomplished using other suitable conditions known to the skilled artisan.
Scheme 6 : Ethyl formate
Figure imgf000074_0001
Sodium / ether 0°Ctort/16h
Figure imgf000074_0002
Ac20(3eq.)/AICI3 10%KOH/EtOH reflux / 1 h
Figure imgf000074_0004
EtCI2/rtto40°C/16h
Figure imgf000074_0003
■- H O 33 34 35
[0134] Scheme 6 above provides a general route for the preparation of starting pyrrole acid 35, wherein Ri4 and Ris are methyl, A is H, Rι8 is absent, Rι8, is =0, U is a bond and Ri6 is methyl. It will be appreciated by those skilled in the art that other pyrrole analogs of interest may be synthesized by modifications of scheme 6.
Scheme 7
Figure imgf000074_0005
Figure imgf000075_0001
37 38
Figure imgf000075_0002
IA-7
[0135] Scheme 7 above provides a general route for the preparation of compounds of formula I and I2-7 wherein V is -C(O), W is -C(0)C(0) -N(R6)2, Ris is absent and Ris- is =N(R'), U is a bond, Riε is R' , A is hydrogen, R2, R4, and R7 are H, R' , Rλ , R3, R5, R5 ,, R6, R9, R9 ,, R10, Rio-, R11, > Ru-, R12, i2', Ri4, and Ri5, are as described in any of the embodiments herein. Protected pyrrole ester 27 (prepared by methods described above in scheme 5 and scheme 6) is condensed with an appropriate amine, according to the procedure in J". Chem. Soc. ■ Chem . Commun . , (6) pp. 634-635 (1986), to give imine 36. TBAF deprotection of both silyl based protecting groups according to the procedure described in «J. Chem. Soc. Perkin Trans . (1) , pp. 2181- 2186 (1986), gives pyrrole imine acid 37. Final coupling and oxidation are accomplished according to the procedures listed above in schemes 1, 3, and 5. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate 38. Likewise the oxidation of intermediate 38 to IA-7 may be accomplished using other suitable conditions known to the skilled artisan.
Scheme 8
Figure imgf000076_0001
43
Figure imgf000076_0002
IA-8
[0136] Scheme 8 above provides a general route for the preparation of compounds of formula I and IA-8 wherein V is -C(O), W is -C(0)C(0) -N(R6)2, Ris is absent and Rι8 , is =CH2, U is nitrogen, R±e is R' wherein R' is acetyl, A is hydrogen, R , R4, and R are H, Rx, R3 , R5, R5, , R6, R9, R9> , Rio, Rio-, R11, Rii', Rι2, Rι2', Rι , and Ri5, are as described in any of the embodiments herein. Condensation of 27 with hydroxylamine using the procedure described in J. Org. Chem. , pp. 5917-5921 (1992), gives oxime 39. Oxime acylation with acetic anhydride followed by thermal rearrangement in pyridine, according to the procedure described in Leibigs Ann . Chem. , (12), pp. 2065-2080 (1986), gives enamide 41. TBAF deprotection of both silyl based protecting groups according to the procedure described in J. Chem . Soc . Perkin Trans . (1), pp. 2181- 2186 (1986), gives pyrrole acid 42. Final coupling and oxidation are accomplished according to the procedures listed above in schemes 1, 3, 5, and 7. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate 43. Likewise the oxidation of intermediate 43 to IA-8 may be accomplished using other suitable cqnditions known to the skilled artisan.
Scheme 9
Figure imgf000077_0001
Figure imgf000078_0001
IA-9
Figure imgf000078_0002
IA-11
[0137] Scheme 9 above provides a general route for the preparation of compounds of formula I, IA-9, and IA-10 wherein V is -C(O), W is -C (0) C (0) -N(R6) 2, Ris is absent and Ris- is =CH , U is oxygen, R16 is -P(O) (OR')2 wherein R' is benzyl (IA-9) or hydrogen (IA-10) , A is hydrogen, R2, R4, and R7 are H, Rx, R3, R5, R5 ,, R6, R9, R9-, Rio, Rio', R11, Ru-, R12, Rι2', R14, and R15, are as described in any of the embodiments herein. The enolate of protected pyrrole ester 27 (prepared as described in the preceding schemes wherein R6 is methyl) is generated with LDA and reacted with dibenzylchlorophosphate according to the method described in Tet. Lett . , pp. 4275-4277 (2003) to give enol phosphate 44. It will be appreciated by those skilled in the art that other enol phosphates of interest may be prepared by the same procedure by adjusting the starting chlorophosphate reagent used. TBAF deprotection of both silyl based protecting groups according to the procedure described in J". Chem. Soc . Perkin Trans . (1), pp. 2181-2186 (1986), gives pyrrole acid 45. Final coupling and oxidation are accomplished according to the procedures listed in any of the schemes above. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate 46. Hydrogenolysis of dibenzyl ester IA-9 using standard palladium catalysis gives free enol phosphonooxy acid IA-10. Likewise the oxidation of intermediate 24 and the deprotection of IA-9 may be accomplished using other suitable conditions known to the skilled artisan.
Scheme 10 :
Figure imgf000079_0001
Figure imgf000080_0001
IA-11
[0138] Scheme 10 above provides a general route for the preparation of compounds of formula I and IA-11 wherein V is -C(O), W is -C:(0) C (0) -N(R6) 2, Ris is absent and Ris- is =CH2, U is oxygen, Ri6 is -C(0)R', A is hydrogen, R2, R4, and R7 are H, R1# R3, R5, R5,, R6, R9, R9 ,
Rio, Rio-, R11, Rii', R12, R12', R14, R15, and Rie, are as described in any of the embodiments herein. The enolate of protected pyrrole ester 27 (prepared as described in the preceding schemes wherein Rι6 is methyl) is generated with LDA and reacted with a suitable acyl chloride to give enol ester 47. TBAF deprotection of both silyl based protecting groups according to the procedure described in J. Chem . Soc. Perkin Trans . (1) , pp. 2181-
1
2186 (1986), gives pyrrole acid 48. Final coupling and oxidation are accomplished according to the procedures listed in any of the schemes above. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate 48. Likewise the oxidation of intermediate 48 may be accomplished using other suitable conditions known to the skilled artisan. Enol ethers wherein Rι8 is absent and Ri8 is =CH2, U is oxygen and R6 is -R' may also be prepared according to the methods listed in scheme 10. For instance to prepare the enol ether analog wherein Rι6 is methyl, the pyrrole enolate generated from LDA treatment of 27 could be reacted with dimethyl sulfate and then carried through the same synthetic sequence described above.
Scheme 11 :
Figure imgf000081_0001
IA-12
[0139] Scheme 11 above provides a general route for the preparation of compounds of formula I and IA-12 wherein V is -C(0), W is -C (0) C (0) -N(R6) 2, are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated ring system; wherein the Ris and Ris- atoms bound to the carbon atom are 0; U is a bond, R16 is -R', A is hydrogen, R2, R4, and R7 are H, R' , Rl t R3, R5, R5', R6, R9, R9-, Rio, Rio- , Rll, Rii-, R12, Ri2', Ri4, R15, and Ri6, are as described in any of the embodiments herein. The pyrrole nitrogen in intermediate 11 (prepared as described in the preceding schemes) is Boc protected under standard conditions to give BOC- protected pyrrole ester 50. Acid catalyzed condensation with an appropriate diol according to the method described in J". Org. Chem pp. 2663-2669 (1984) , gives ketal 52 which is hydrolized under basic conditions to give the pyrrrole acid 53. Final coupling and oxidation are accomplished according to the procedures listed in any of the schemes above. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediate 54. Likewise the oxidation of intermediate 54 may be accomplished using other suitable conditions known to the skilled artisan.
Scheme 12
Figure imgf000082_0001
[0140] Scheme 12 above in combination with scheme 1 above provides a general route for the preparation of compounds of formula I and IH wherein V is -C(O), W is - C(0)C(0) -N(R6)2, R2, R4, and R7 are H, and Ri; R3, R5, R5', Re , R9, R9', R11, Rii', R12, R12', Ri4, R15, Riε, Ris, Ris' , n., A, U, Z, and Z' are as described in any of the embodiments herein. Scheme 12 above in combination with scheme 1 also provides a general route for the preparation of compounds of formula I and IK using modifications (e.g. other appropriate commercially available starting materials) known to those skilled in the art.
Scheme 13 :
Figure imgf000083_0001
[0141] Scheme 13 above in combination with scheme 1 above provides a general route for the preparation of compounds of formula I and IK wherein V is -C(O) , W is - C(0)C (0) -N(R6)2, R2, R4, and R7 are H, Rio, and Rio- are fluoro, and Rx , R3 , R5, R5-, Re, R9, R9-, R11, Ru-, Rι2, R12', R14, R15, Rie, Ris, Ris-, A, and U, are as described in any of the embodiments herein.
Scheme 14 :
Figure imgf000084_0001
61
Figure imgf000084_0002
IL-1
[0142] Scheme 14 above provides a general route for the preparation of compounds of formula I, IL, and IL-1 wherein V is -C(O), W is -C (0) C (O) -N(R6)2, R2, R4, R7, Rg, R9», Rio-, Rii* and Ru-, are H, Rio- is OR1, and Ri, R3, R5, δ'i R6 Ri4ι R15, Ri6, Ris, is-, A, and U, are as described in any of the' embodiments herein. As would be appreciated by any skilled practitioner, compound 67 may be carried on to compounds of formula IL-1 by routine methods . Additionally, other suitable and commercially available coupling reagents may be used to prepare intermediates 64, 65, 67, and 68. Likewise, the oxidation of intermediate 68 to compounds of formula IL-1 may be accomplished using other suitable conditions known to the skilled.? artisan.
Scheme 15 :
-
Figure imgf000085_0001
70 71
Figure imgf000085_0002
Figure imgf000086_0001
[0143] Scheme 15 above, depicts an alternative approach to preparing compounds of formula IL and IL-1 of this invention wherein V is -C'(O), W is -C (0) C (0) -N(R6) 2 , R2 , R4, R7, R9, Rg,, Rie Ru, and Ru-, are H, Ri0' is OR', and Ri, R3, R5, R5', Re, Ri4, Ris, Rie, Ris, Ris-, A, and U, are as described in any of the embodiments herein. In this approach, a 4-hydroxyproline derivative 69 is reacted with a commercially available R' -halide (such an aryl chloride), represented by R'-X, in the presence of a suitable base (such as potassium t-butoxide) to provide a compound 70. As would be appreciated by any skilled practitioner, compound 70 may be carried on to compounds of formula IE-1 by routine methods. Additionally, other suitable and commercially available coupling reagents may be used I to prepare intermediates 72, 73, 7 ff and 75.
Likewise, the oxidation of intermediate 75 to compounds of formula IL-1 may be accomplished using other suitable conditions known to the skilled artisan .
Scheme 16
as in Scheme 1
Figure imgf000086_0002
Figure imgf000087_0001
IM-1
[0144] Scheme 16 in combination with scheme 1 above provides a general route for the preparation of compounds of formula IM, and IM-1 wherein V is -C(O), W is - C(0)C(0)-N(R6)2, 2, R4, R7, R9, Rg-, Rio-, and Ru., are H, Rio and Ru are taken together with the ring atoms to which they are bound to form a ring system as defined in any of the embodiments and Ri, R3, R5, R5', Re , Rι , R15, Rie, Ris, Ris-, A, and U, are as described in any of the embodiments herein. Bicyclic starting materials such as compound 76 may be any commercially available reagents of interest or may be synthesized according to literature methods known to the skilled artisan. After coupling of 76 to intermediate 2, resulting intermediate 80 may be carried on to compounds of formula IM-1 by the methods described in scheme 1. Scheme 16 in combination with scheme 1
[0145] Compounds of this invention represented by formula IN may also be prepared from commercially available amino acid derivatives by the route described in schemes 1 and 16 above. If a starting amino acid analogue of interest is not commercially available it may be prepared according to literature methods known to those skilled in the art.
Scheme 17 :
Figure imgf000088_0001
81
Figure imgf000088_0002
70 h @ rt
82 83
Figure imgf000088_0003
84
[0146] Scheme 17 above provides a synthetic route for the preparation of Cbz-protected azabicyclo [2.2. l]heptane-3-carboxylic acid, compound 33 and the corresponding t-butyl ester, compound 84. The free acid 83 may be further elaborated by the route defined in scheme 1 above to prepare compounds of formula I and 10. [0147] The preparation of various other optionally substituted multicyclic azaheterocyclyls intermediates to prepare compounds of formulae I and IN via schemes 1, 14 or 15 above, may be accomplished by the methods described in PCT publication No. WO 02/18369 and references cited therein. [0148] Various 3, 4, and 5-substituted proline analogues may either be purchased commercially or prepared according to known literature procedures . For instance, for compounds of formula I wherein R9- is (C1-C12) -aliphatic-, the starting 3-substituted proline analogues may be prepared according to the method of Holladay, M.W. et al . , J. Med. Chem. , 34, pp. 457-461 (1991). For compounds of formula I wherein either Rg-, Rio-, or Ru- are cyclohexyl and Rg, Rio, or Ru are hydrogen, the cyclohexyl proline intermediates may be prepared by platinum oxide reduction of the commercially available phenyl substituted proline analogues. Such reduction conditions are well known to those skilled in the art. For compounds of formula I wherein R9- is (C1-C12) -aliphatic- and Rio- is (C1-C12 ) -aliphatic-, the starting 3 , 4-disubstituted proline analogues may be prepared according to t e method of Kanamasa, S. et al . , J". Org. Chem, 56, pp. 2875-2883 (1991) . In each of the syntheses involving 3, 4, or 5-substituted prolines or 3 , 4-disubstituted prolines, the intermediates may be further elaborated by the routes defined above in schemes 1, 14, or 15 to prepare compounds of formula I.
[0149] Accordingly, one embodiment of this invention provides a process for preparing a compound of formula I, as defined in any of the embodiments herein, comprising the step of: reacting a compound of formula VII in the presence of a compound of formula VIII ,to provide a compound of formula IX:
Figure imgf000089_0001
VII VIII IX wherein:
R2ι is an amine protecting group, a P3- residue of an HCV protease inhibitor described herein, or a P4-P3- residue of an HCV protease inhibitor as described herein, and wherein the P3 and the P4-P3 residues are optionally protected with an amino-terminal capping group; R20 is a carboxy protecting group or a Pi residue of an HCV protease inhibitor described herein, wherein the Pi residue is optionally protected with a carboxy terminal protecting group or with W. R' is as defined in any of the embodiments herein. X is an appropriate leaving group. As would be appreciated by skilled practitioners, an appropriate leaving group may be generated in situ. [0150] In an alternative embodiment, the 4-hydroxy group in formula VII may be converted to a leaving group. In such an embodiment, X is a nucleophilic oxygen which reacts with VII to provide IX.
[0151] As used herein, Pi, P3 , P4 refer to the residues of an HCV protease inhibitor as defined in the art and as are well known to -skilled practitioners. [0152] The compound of formula IX may be carried on to a compound of formula I according to the methods described herein.
[0153] Although certain exemplary embodiments are depicted and described below, it will be appreciated that compounds of this invention can be prepared according to the methods described generally above using appropriate starting materials generally available to one of ordinary skill in the art. [0154] Another embodiment of this invention provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof. According to a preferred embodiment, the compound of formula I is present in an amount effective to decrease the viral load in a sample or in a patient, wherein said virus encodes a serine protease necessary for the viral life cycle, and a pharmaceutically acceptable carrier. [0155] If pharmaceutically acceptable salts of the compounds of this invention are utilized in these compositions, those salts are preferably derived from inorganic or organic acids and bases . Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. [0156] Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others . Water or oil-soluble or dispersible products are thereby obtained. [0157] The compounds utilized in the compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion. [0158] Pharmaceutically acceptable carriers that may be used in these compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or \ electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers , polyethylene glycol and wool fat . [0159] According to a preferred embodiment, the compositions of this invention are formulated for pharmaceutical administration to a mammal, preferably a human being. [0160] Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally or intravenously. [0161] Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides . Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically- acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions . These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions . Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
[0162] Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of antiviral, particularly anti-HCV mediated disease. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w) . Preferably, such preparations contain from about 20% to about 80% active compound. [0163] When the compositions of this invention comprise a combination of a compound of formula I and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen.
[0164] The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers that are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added. [0165] Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These may be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols . [0166] The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs. [0167] Topical application for the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
[016,8] For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers . Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions may be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[0169] For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
[0170] The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents . [0171] Most preferred are pharmaceutical compositions formulated for oral administration.
[0172] In one embodiment, the compositions of this invention additionally comprise another agent, preferably a cytochrome P-450 inhibitor. Such cytochrome P-450 inhibitors include, but are not limited to, ritonavir.
[0173] In another embodiment, the compositions of this invention additionally comprise another anti-viral agent, preferably an anti-HCV agent. Such anti-viral agents include, but are not limited to, immunomodulatory agents, such as -, β-, and γ-interferons, pegylated derivatized interferon- compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors) ; inhibitors of other targets in the HCV life cycle, including helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., VX-497 and other IMPDH inhibitors disclosed in United States Patents 5,807,876 and
6,498,178, mycophenolic acid and derivatives thereof); inhibitors of cytochrome P-450, such as ritonavir, or combinations of any of the above. [0174] Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms . [0175] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the , activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredients will also depend upon the particular described compound and the presence or absence and the nature of the additional anti-viral agent in the composition.
[0176] According to another embodiment, the invention provides a method for treating a patient infected with a virus characterized by a virally encoded serine protease that is necessary for the life cycle of the virus by administering to said patient a pharmaceutically acceptable composition of this invention. Preferably, the methods of this' invention are used to treat a patient suffering from a HCV infection. Such treatment may completely eradicate the viral infection or reduce the severity thereof. More preferably, the patient is a human being.
[0177] In an alternate embodiment, the methods of this invention additionally comprise the step of administering to said patient an anti-viral agent preferably an anti- HCV agent. Such anti-viral agents include, but are not limited to, immunomodulatory agents, such as α-, β-, and γ-interferons, pegylated derivatized interferon-α compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors) ; inhibitors of other targets in the HCV life cycle, including but not limited to helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., VX-497. and other IMPDH inhibitors disclosed in United States Patents 5,807,876 and 6,498,178, mycophenolic acid and derivatives thereof); inhibitors of cytochrome P-450, such as ritonavir, or combinations of any of the above.
[0178]- Such additional agent may be administered to said patient as part of a single dosage form comprising both a compound of this invention and an additional antiviral agent. Alternatively the additional agent may be administered separately from the compound of this invention, as part of a multiple dosage form, wherein said additional agent is administered prior to, together with or following a composition comprising a compound of this invention. [0179] In yet another embodiment the present invention provides a method of pre-treating a biological substance intended for administration to a patient comprising the step of contacting said biological substance with a pharmaceutically acceptable composition comprising a compound of this invention. Such biological substances include, but are not limited to, blood and components thereof such as plasma, platelets, subpopulations of blood cells and the like; organs such as kidney, liver, heart, lung, etc; sperm and ova; bone marrow and components thereof, and other fluids to be infused into a patient such as saline, dextrose, etc.
[0180] According to another embodiment the invention provides methods of treating materials that may potentially come into contact with a virus characterized by a virally encoded serine protease necessary for its life cycle. This method comprises the step of contacting said material with a compound according to the invention. Such materials include, but are not limited to, surgical instruments and garments (e.g. clothes, gloves, aprons, gowns, masks,, eyeglasses, footwear, etc.); laboratory instruments and garments (e.g. clothes, gloves, aprons, gowns, masks, eyeglasses, footwear, etc.); blood collection apparatuses and materials; and invasive devices, such as shunts, stents, etc.
[0181] In another embodiment, the compounds of this invention may be used as laboratory tools to aid in the isolation of a virally encoded serine protease. This method comprises the steps of providing a compound of this invention attached to a solid support; contacting said solid support with a sample containing a viral serine protease under conditions that cause said protease to bind to said solid support; and eluting said serine protease from said solid support. Preferably, the viral serine protease isolated by this method is HCV NS3-NS4A protease.
[0182] In order that this invention be more fully understood, the following preparative and testing examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.
EXAMPLES [0183] 1H-NMR spectra were recorded at 500 MHz using a Bruker AMX 500 instrument. Mass spec, samples were analyzed on a MicroMass ZQ or Quattro II mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using flow injection (FIA) or chromatography. Mobile phase for all mass spec, analysis consisted of acetonitrile-water mixtures with 0.2% formic acid as a modifier. [0184] As used herein, the term wRt(min)" refers to the HPLC retention time, in minutes, associated with the compound. The HPLC retention times listed were either obtained from the mass spec, data or using the following method:
Instrument: Hewlett Packard HP-1050; Column: YMC Cι8 (Cat. No. 326289C46);
Gradient/Gradient Time: 10-90% CH3CN/H20 over 9 minutes, then 100% CH3CN for 2 minutes; Flow Rate: 0.8ml/min; Detector Wavelength: 215nM and 245nM. [0185] Chemical naming for selected compounds herein was accomplished using the naming program provided by CambridgeSoft Corporations ChemDraw Ultra®, version 7.0.1. Example 1 3-Acetyl-4,5-dimethyl-2-pyrrole carboxylic acid (35). [0186] A solution of sodium nitrite (36.9 g, 0.534 mol) in 70 mL of water was added dropwise to a stirred solution of ethylacetoacetate (70 g, 0.538 mol) in 1401 mL of glacial acetic acid at 0°C. After the addition was complete, the light yellow reaction mixture was allowed to warm to room temperature. After 30 minutes, all the starting material had been consumed, the reaction was quenched with 350 mL of water and extracted with ethyl acetate (2 X 125 mL) . The organic extracts were combined and washed with water (2 X 125 mL) and saturated sodium hydrogen carbonate aqueous solution (2 X 105 mL) . The organic layer was dried with sodium sulfate and concentrated in vacuo to give 84.2 g (98%) of ethyl-2- hydroxyimino-3-oxobutanoate 31 as a pale yellow oil. NMR (CDC13) d 10.3 (s,lH), 4.2 (q,2H), 2.3 (s,3H), 1.3 (t, 3H) ppm. [0187] Crushed sodium (12.4 g, 0.540 mol) was added to a solution of 2-butanone (48.2 mL, 0.538 mol) and ethyl formate (43.47 mL, 0.538 mol) in dry ether (540 mL) with vigorous mechanical stirring over a period of 1 h, during which time the mixture was chilled in an ice-salt bath. The mixture was then stirred at room temp, for 14 h. After cooling the reaction mixture to 4°C for a few hours, the precipitated sodium salt was obtained by filtration and washed thoroughly with cold, dry ether to afford 49.3 g (75%) of the desired sodium salt of 2-Methy-3- oxobutyraldehyde 32. 1H NMR (DMSO-d6) d 9.1 (s,lH), 1.9 (s,3H) , 1.3" (s,3H) ppm.
[0188] Sodium salt 32 (49.3 g, 0.404 mol) and oxime 31 (64.23, 0.404 mol) were stirred in 300 mL of 70% acetic acid/ 30% water and warmed to 50°C. Zinc powder (42.21 g, 0.646 mol) was added portion-wise over 30 minutes maintaining the temperature below 100°C. When the addition was complete, the suspension was refluxed for 15 minutes, then poured into 4 L of ice-water. After a short time, the product precipitated out to give, after filtration, 30.1 g (45%) of the desired ethyl-4,5- dimethyl-2-pyrrole carboxylate 33. 1H NMR (CDC13) d 9.0 (bs,lH), 6.7 (s,lH), 4.3 (q,2H), 2.3 (s, 3H) , 2.0 (s,3H), 1.3 (t,3H) ppm. [0189] To a solution of aluminum chloride (50.19 g, 0.376 mol) in dry dichloroethane (580 mL) at 25°C was added slowly acetic anhydride (17.75 mL, 0.188 mol). The resulting mixture was stirred at room temp, for 10 minutes, then a solution of pyrrole 33 (10.49 g, 0.0627 mol) in dichloroethane (30 mL) was added and the reaction mixture was stirred at room temp, for 2h. After an additional 3h at 80°C, the mixture was poured into ice water and extracted with dichloromethane. The organic layer was dried with anhy. sodium sulfate and concentrated in vacuo to an orange residue. Short plug filtration over silica gel (30% ethyl acetate / 70% hexanes) gave 7.5 g
(60%) of ethyl-3-acetyl-4, 5-dimethyl-2-pyrrol,e carboxylate 34. XH NMR (CDC13) d 9.0 (bs,lH), 4.3 (q,2H), 2.7 (s,3H), 2.1 (s, 3H) , 1.9 (s,3H), 1.3 (t,3H) ppm. [0190] A mixture of pyrrole ester 34 (8.2 g, 0.0392 mol) , in ethanol and 100 mL of 10% potassium hydroxide were refluxed for 1 h. The mixture was cooled and concentrated in vacuo to an oil . Water was added to the oil, the mixture acidified with dilute HCl and extracted with ether. The organic phase was dried with anhy. sodium sulfate and concentrated in vacuo to a solid residue. The compound was recrystallized in 80 mL of ethanol to give 5.8 g of pure 3-acetyl-4, 5-dimethyl-2-pyrrole carboxylic acid 35 as a solid. 2H NMR (DMSO-d6) d 2.5 (s,3H), 2.2 (s,3H) , 2.0 (s,3H) ppm.

Claims

CLAIMS We claim:
1.. A compound of formula I:
Figure imgf000103_0001
I or a pharmaceutically acceptable salt thereof, wherein:
R9 and R9< are each independently: hydrogen- ,
(C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl-,
[ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12 ) - aliphatic- ,
(Cβ-ClO)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-,
(C3-C10) -heterocyclyl-,
(C3-C10) -heterocyclyl- (C1-C12) aliphatic- ,
(C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to three aliphatic carbon atoms in each of Rg and R- are optionally replaced by 0, N, NH, S,
SO, or S02 in a chemically stable arrangement; wherein each of R9 and Rg, is independently and optionally substituted with up to 3 substituents independently selected from J;
J is halogen, -OR', -N0 , -CN, -CF3, -OCF3, -R' , oxo, thioxo, =N(R'), =N(0R'), 1, 2-methylenedioxy, 1,2- ethylenedioxy, -N(R')2, -SR' , -SOR' , -S02R', -S02N(R')2, -S03R', -C(0)R', -C(0)C(0)R', -C (0) C (0) OR' , -C(0)C(0)N(R' )2, -C(0)CH2C(0)R' , -C(S)R', -C(S)OR\ -C(0)OR', -OC(0)R', -C(0)N(R')2, -OC (O)N(R' ) 2, -C(S)N(R')2, -(CH2)0-2NHC(O)R' , -N (R' ) N (R' ) COR' , -N(R' )N(R' )C(0)OR' , -N(R' )N(R' )CON(R' )2, -N(R')S02R', • -N(R' )S02N(R' )2, -N(R' )C(0)0R' , -N (R' ) C (0) R' ,
-N(R' )C(S)R' , -N(R' )C(0)N(R' )2, -N(R' ) C (S)N(R' ) 2, -N(COR' )COR' ,
Figure imgf000104_0001
-C (=NH) N (R' ) 2, -C (O)N (OR' ) R' , -C(=NOR')R', -OP(0) (OR' )2, -P(0) (R')2, -P(0) (OR')2, or -P(O) (H) (OR' ) ; wherein; each R' is independently selected from: hydrogen- , (C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-CIO) -cycloalkyl or -cycloalkenyl] - (C1-C12 ) - aliphatic-,
(Cβ-ClO)-aryl-,
(C6-C10 ) -aryl- (C1-C12 ) aliphatic- , (C3-CIO ) -heterocyclyl- ,
(C3-CIO) -heterocyclyl- (C1-C12 ) aliphatic-, i (C5-C10) -heteroaryl-, and
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J; wherein two R' groups bound to the same atom optionally form a 5- to 6-membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, and S0 , wherein said ring is optionally fused to a (C6-C10) aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, or a (C3-C10) heterocyclyl, wherein any ring has up to 3 substituents selected independently from J; Rio, Rie, Ru, and Ru- are each independently: hydrogen- ,
(C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-CIO) -cycloalkyl or -cycloalkenyl] - (C1-C12) - aliphatic-, (Cδ-ClO)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-CIO) -heterocyclyl-,
(C3-C10) -heterocyclyl- (C1-C12) aliphatic-, (C5-C10) -heteroaryl-, or (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein any ring is optionally fused to a (G6-Cl0)aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or (C3-CIO) eterocyclyl; wherein up to 3 aliphatic carbon atoms in each of Rio, Rio-, Ru, and Ru- are optionally replaced by a heteroatom selected from 0, NH, S, SO, or S02 in a chemically stable arrangement; wherein each of R0, Rie, Ru, and Ru- is independently and optionally substituted with up to 3 substituents independently selected from J; or is -OR' and Rio- is H; or and Rio- are both -OR' or -SR' ; or and Rie are both fluorine; or and Ro- are optionally taken together with the carbon atom to which they are bound to form a 5- to .7-membered saturated or partially unsaturated ring system; wherein the Rio and Rio- atoms bound to the carbon atom are independently C (H) , N, NH, 0, S, SO, or S02; wherein said ring optionally contains up to 4 heteroatoms independently selected from N, NH, 0, S, SO, and S02; wherein any atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; and wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, and a (C3-CIO) heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; or
Rg and Rio are optionally taken together with the ring atoms to which they are bound to form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system up to 3 heteroatoms independently selected from N, NH, 0, S, SO, or S02; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; or
Rio and Ru are optionally taken together with the ring atoms to which they are bound to form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, or S0 ; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
Rg and Ru are optionally taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic or heterocyclic ring system containing up to 10 atoms; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; wherein each heteroatom in the heterocyclic ring system is selected from the group consisting of N, NH, 0, S, SO, or S02;
Ri and R are each independently: (C1-C12 ) -aliphatic- , (C3-C10) -cycloalkyl- or -cycloalkenyl-,
[ (C3-C10) -cycloalkyl- or -cycloalkenyl] - (C1-C12) - aliphatic-,
(C6-C10) -aryl- (C1-C12) aliphatic-, or
(C5-C10 ) -heteroaryl- (C1-C12 ) -aliphatic- ; wherein up to 3 aliphatic carbon atoms in each of Ri and R3 are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, or S02 in a chemically stable arrangement; wherein each of Ri and R3 is independently and optionally substituted with up to 3 substituents independently selected from J; R2, R4, and R7 are each independently: hydrogen-, (C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- (C1-C12) -aliphatic-, or (C6-C10) -aryl- (C1-C12) -aliphatic- ; wherein up to two aliphatic carbon atoms in each of R2, R, and R7 are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, and S02 in a chemically stable arrangement; , wherein each of R2, R, and-R is optionally substituted with up to 3 substituents independently selected from J; R5 and Rs> are each independently hydrogen or (C1-C12)- aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R5 is optionally substituted with sulfhydryl or hydroxy; or R5 is Ph or -CHPh and R5< is H, wherein said Ph or -CH2Ph group is optionally substituted with up to 3 substituents independently selected from J; or R5 and R5. together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, 0, SO, and S02; wherein said ring is optionally substituted with up to 2 substituents selected independently from J; W is:
Figure imgf000108_0001
Figure imgf000108_0002
Figure imgf000109_0001
wherein m is 0 or 1; wherein each R6 is independently: hydrogen- ,
(C1-C12 ) -aliphatic- ,
(C6-Cl0)-aryl-,
(C6-C10)-aryl- (C1-C12 ) aliphatic-,
(C3-CIO) -cycloalkyl- or cycloalkenyl-,
[ (C3-C10) -cycloalkyl- or cycloalkenyl] - (C1-C12 ) - aliphatic-,
(C3-C10) -heterocyclyl-,
(C3-C10) -heterocyclyl- (C1-C12) -aliphatic- ,
(C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 3 aliphatic carbon atoms in each R is optionally replaced by a heteroatom selected from 0, NH, S, SO, or S02 in a chemically stable arrangement; wherein Re is optionally substituted with up to 3 J substituents; or two R groups, together with the nitrogen atom to which they are bound, optionally form a 5- to 6- membered aromatic or a 3- to 7-membered saturated or partially unsaturated ring system having up to 3 heteroatoms independently selected from N, NH, 0, S, SO, and S02, wherein said ring is optionally fused to a (C6-Cl0)aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or a (C3-CIO)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J; wherein each R8 is independently -OR' ; or the Rs groups together with the boron atom, is a (C3-C10)- membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N,
NR' , 0, SO, and S0 ; V is -C(0)-, -C(S)-, -S(0)-, or -S(0)2-; A is hydrogen or -C(Ri2) (Ri2- ) -T-Ri3; T is oxygen or a bond; Ri2 and Rι- are each independently: hydrogen- , or
(C1-C6) -aliphatic-; wherein up to two aliphatic carbon atoms in each of
Rι and Ri2- are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, and S02 in a chemically stable arrangement; or Rι is absent and Rι2> is =0;
Ri3 is -C(0)R', -P(0)(0R')2, -S03R\ -R', or Ru; Rig is : hydrogen,
(C1-C12 ) -aliphatic- ,
(C6-C10) -aryl- (C1-C12) aliphatic-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 3 aliphatic carbon atoms in each Rι9 is optionally replaced by a heteroatom selected from 0,
NRig, S, SO, or S0 in a chemically stable arrangement; wherein up to 3 aliphatic carbon atoms in each Rig is optionally replaced with -C(0)-; wherein Rig is optionally substituted with up to 3 J substituents; wherein any NRι9, taken together with the nitrogen and a carbon adjacent to the nitrogen, optionally forms a 5- to 7-membered ring system, wherein said ring system optionally contains up to three additional heteroatoms selected from 0, N, NH, S, SO, and S02 in a chemically stable arrangement; Ri4 and R15 are independently halogen, -OR', -0C (O)N(R' )2,
-N02, -CN, -CF3, -0CF3, -R', 1 , 2-methylenedioxy, 1,2- ethylenedioxy, -N(R')2, -SR', -SOR' , -S02R' , -S02N(R')2, -S03R', -C(0)R\ -C(0)C(0)R', -C (0) CH2C (0) R ' , -C(S)R', -C(0)OR', -OC(0)R\ -C(0)N(R')2, -OC (O)N(R' ) 2, -C(S)N(R')2, or -(CH2)0-2NHC(O)R' ; Rie is R', -C(0)R', -P(0)(OR')2, or -S03R' ; U is 0, N, or a bond; and
Ris and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the Rι8 and Ris- atoms bound to the carbon atom are independently 0 or N; wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, O, S, SO, and S02; wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, and a (C3-C10) heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; provided that when Rι8 and Ris- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system, then Ri6 is R' ; or Ris' is =0, =CH2, =N(R'), or =N(OR') and Ris is absent, provided that when Ris is absent and Ris- is =CH2, then U is oxygen; and provided that when Rι8 is absent and Ris- is =0, =N(R') or =N(0R' ) , then U is a bond and Ri6 is R' .
2. The compound according to claim 1, wherein V is -C(0)-.
3. The compound according to claim 2, wherein: A is -C(Rι2) (Ri2')-T-R13;
R12 and Ri2- are both hydrogen; T is oxygen;
Ri3 is -C(0)R\ -P(0) (OR' )2, -S03R', or -R' ; Ri4 and R15 are both -R'; Ris- is =0 and Rι8 is absent; U is a bond; and
Ri6 is R', wherein R' is selected from: I (C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12) - aliphatic- ; wherein up to 5 atoms in R' are optionally and independently substituted with J.
4. The compound according to cla.im 3, wherein: RX3 is -C(0)R', -P(0)(OR')2, or -R' ;
Ri4 and Ri5 are both -R' and R' is (C1-C12 ) -aliphatic-; and Rie is R', wherein, R' is (C1-C12 ) -aliphatic- .
5. The compound according to claim 2, wherein: A is -C(Ri2) (R12 -T-R13;
R12 is hydrogen and Rι , is (C1-C6) -aliphatic- ; wherein up to two aliphatic carbon atoms in Ri - are optionally replaced by a heteroatom selected from 0, N, NH, S, SO, and S02 in a chemically stable arrangement;
T is oxygen;
R13 is -C(0)R\ -P(0)(OR')2, -S03R', or -R';
Rι and R15 are both -R' ;
Ris- is =0 and Rι8 is absent;
U is a bond; and
Ri6 is R' , wherein R' is selected from: (C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12 ) - aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J.
6. The compound according to claim 5, wherein: Ri3 is -C(0)R', -P(0)(OR')2, or -R';
R14 and Ri5 are both -R' and R' is (C1-C12) -aliphatic-; Rie is R', wherein R' is (C1-C12) -aliphatic- ;
7. The compound according to claim 2, wherein: A is -C(Rι2) (Ri2')-T-Rι3;
R12 is absent and Rι2- is =0; T is oxygen or a bond;
Ri3 is -Rig;
Ri4 and R15 are both -R ' ;
Ris- is =0 and Ri8 is absent ;
U is a bond; and
Ri6 is R' , wherein R' is selected from:
(C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-,
[ (C3-CIO) -cycloalkyl or -cycloalkenyl] - (C1-C12 ) - aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J.
8. The compound according to claim 2, wherein: Ris- is =CH2, and Rι8 is absent;
U is oxygen;
Rie is R', -C(0)R', -P(0)(0R')2, or -S03R';
R14 and Rχ5 are both -R ' ; and
A is hydrogen.
9. The compound according to claim 8, wherein: Rie is R\ -C(0)R\ or -P(0)(OR')2;
Rι and Ri5 are both -R' and R' is (C1-C12) -aliphatic- .
10. The compound according to claim 2, wherein: Ris- is =N(R') or =N(OR') and Ri8 is absent; U is a bond; Rie is R' ;
Rι and Rι5 are both -R' ; and A is hydrogen. \
11. The compound according to claim 10, wherein: R14 and Ri5 are both -R' and R' is (C1-C12 ) -aliphatic- .
12. The compound according to claim 2, wherein:
Ris and Ri8- are optionally taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring system; wherein the R8 and R18' atoms bound to the carbon atom are independently 0 or N; wherein said ring optionally contains up to 1 additional heteroatom selected from N, NH, 0, S, SO, and S02; wherein any substitutable atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; wherein said ring is optionally fused to a second ring selected from (C6-C10) aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, and a (C3-C10) heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; U is a bond; Ri6 is R' ; R14 and R15 are both -R ' ; and A is hydrogen.
13. The compound according to claim 12; wherein the Rι8 and Rι8' atoms bound to the carbon atom are 0; wherein said ring optionally contains up to 1 additional oxygen atom.
14. The compound according to any one of claims 1- 13, wherein Ri4 and R15 are both -R? and R' is (C1-C6) -aliphatic- .
15. The compound according to claim 14, wherein Ri4 and Ri5 are both methyl.
16. The compound according to any one of claims 1- 15, wherein the
Figure imgf000115_0001
wherein: n is 0, 1, or 2;
Z and Z' are independently C(H), N, NH, 0, or S;
R9, Rg-, Ru, and Ru- are as defined in claim 1; and the spirocyclic ring containing Z and Z' is optionally substituted with up to 3 J substituents, wherein J is as defined in claim 1.
17. The compound according to claim 16, wherein: radical is :
Figure imgf000116_0001
Figure imgf000116_0002
wherein :
Ru and Ru- are both H; n is 0, 1, or 2;
Rg and "Rg, are as defined in claim 1; and the spirocyclic ring containing Z and Z' is optionally substituted with up to 3 J substituents, wherein J is as defined in claim 1.
18. The compound according to claim 17, wherein the
radical is :
Figure imgf000116_0003
wherein : n is 0 or 1.
19. The compound according to any one of claims 1- 15, wherein the radical is :
Figure imgf000117_0001
wherein :
R9, Rg,, Rie, Ru, and Ru- are as defined in claim 1; and
R' is:
(C6-C10)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10) -heterocyclyl-,
(C3-C10) -heterocyclyl- (C1-C12) aliphatic-, (C5-C10) -heteroaryl-, or (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J.
20. The compound according to claim 19, wherein the
Figure imgf000117_0002
wherein the R' ring is optionally substituted with up to 5 substituents independently selected from J.
21. The compound according to any one of claims 1-15, wherein the radical is :
Figure imgf000118_0001
Rg, Rg-, Rio-, Ru, and Ru- are as defined in claim 1 ; and
R' is selected from:
(C6-C10) -aryl- (C1-C12) aliphatic-,
(C3-C10) -heterocyclyl- (C1-C12 ) aliphatic- , and
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein up to 5 atoms in R' are optionally and independently substituted with J.
22. The compound according to claim 21, wherein the
Figure imgf000118_0002
23. The compound according to any one of claims 1- 15, wherein in the
radical
Rg, Rio, Rio-, Ru, and Ru- are as defined in claim 1; and
Rg- is: (C1-C12 ) -aliphatic- ,
(C3-C10) -cycloalkyl- or -cycloalkenyl-; wherein up to three aliphatic carbon atoms in R9< may be replaced by 0, N, NH, S, SO, or S02; and wherein Rg' is independently and optionally substituted with up to 3 substituents independently selected from J.
24. The compound according to claim 23, wherein the
Figure imgf000119_0001
radical is :
Figure imgf000119_0002
25. The compound according to any one of claims 1- , wherein in the
Figure imgf000119_0003
radical
Rg, R-, Rio, Rie, and Ru are H; and
Ru- is: (C1-C12 ) -aliphatic- , (C3-C10) -cycloalkyl- or -cycloalkenyl-, (C6-Cl0)-aryl-, wherein any ring is optionally fused to a (C6-Cl0)aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or (C3-CIO) heterocyclyl; wherein up to 3 aliphatic carbon atoms in Ru- may be replaced by a heteroatom selected from 0, NH, S, SO, or S02 in a chemically stable arrangement; wherein Ru-, is independently and optionally substituted with up to 3 substituents independently selected from J.
26. The compound according to claim 25, wherein the formula I, the
Figure imgf000120_0001
radical is:
Figure imgf000120_0002
27. The compound according to any one of claims 1- 15, wherein in the
Figure imgf000120_0003
radical
R9, Rio, Ru, and Ru- are H; and
R9 , and Rio- are: (C1-C12) -aliphatic-, ; >
(C3-C10) -cycloalkyl- or -cycloalkenyl-, wherein up to 3 aliphatic carbon atoms in Rg- and Rio- may be replaced by a heteroatom selected from 0, NH, S, SO, or S02 in a chemically1 stable arrangement; and wherein Rg- and Rι0- are independently and optionally substituted with up to 3 substituents independently selected from J.
28. The- compound according to claim 27, wherein the
Figure imgf000120_0004
radical is :
Figure imgf000121_0001
29. The compound according to any one of claims 1- 15, wherein the
radical is
Figure imgf000121_0002
wherein; ring A is a 5- to 6-membered aromatic or a 3- to 7-membered non-aromatic ring system having up to 3 heteroatoms independently selected from N, NH, 0, SO, or S0 ; wherein said ring A is optionally fused to a (C6- ClO)aryl, (C5-C10) heteroaryl, (C3-C10) cycloalkyl, or (C3- C10) heterocyclyl ; wherein any ring has up to 3 substituents selected independently from J; and
Rg, Rg<, Rie, and Ru- are as defined in claim 1.
30. The compound according to claim 29, wherein the
Figure imgf000121_0003
radical is
Figure imgf000121_0004
31. The compound according to claim 30, wherein the
Figure imgf000122_0001
radical is :
Figure imgf000122_0002
32 . The -.compound according to claim 31 , wherein the
Figure imgf000122_0003
radical is
Figure imgf000122_0004
33. The compound according to any one of claims 1- 15, wherein the
Figure imgf000122_0005
wherein: ring B forms a 3- to a 20-membered carbocyclic or heterocyclic ring system; wherein each ring B is either aromatic or nonaromatic; wherein each heteroatom in the heterocyclic ring system is N, NH, 0, SO, or S02; wherein ring B is optionally fused to a (C6- C10)aryl, (C5-C10) heteroaryl, (C3-CIO) cycloalkyl, or (C3- Cl0 ) heterocyclyl ; wherein each ring has up to 3 substituents selected independently from J; and
Rg- and Rn- are as defined in claim 1.
34. The compound according to claim 33, wherein the
Figure imgf000123_0001
radical is
Figure imgf000123_0002
35. The compound according to any one of claims 1- 34, wherein W is:
Figure imgf000123_0003
wherein in the W, the NR6R6 is selected from -NH- (C1-C6 aliphatic), -NH-(C3-C6 cycloalkyl), -NH-CH (CH3) -aryl, or -NH-CH(CH3) -heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with up to 3 halogens-.
36. The compound according to claim 35, wherein in the W, the NRεRε is :
Figure imgf000124_0001
37 . The compound according to claim 36 , wherein in the W, the NR6R6 is : '■
Figure imgf000124_0002
38. The compound according to claim 37, wherein in the W, the NR6R6 is :
Figure imgf000124_0003
39. The compound according to claim 38, wherein in the W, the NR6R6 is :
Figure imgf000124_0004
40. The compound according to any one of claims 1- 39, wherein R5. is hydrogen and R5 is:
Figure imgf000125_0001
41. The compound according to claim 40, wherein R5. is hydrogen and R5 is :
Figure imgf000125_0002
42. The compound according to any one of claims 1- 41, wherein R2, R4, R7, and Rι2, are each independently H, methyl, ethyl , or propyl .
43. The compound according to claim 42, wherein R2, R4, R7, and Rι2- are each H.
44. The compound according to any one of claims 1-
I
43 , wherein R3 is :
Figure imgf000125_0003
45. The compound according to claim 44, wherein R3
Figure imgf000125_0004
46. The compound according to claim 45, wherein R3
I S :
Figure imgf000126_0001
47. The compound according to any one of claims 1- 46, wherein R1 is:
Figure imgf000126_0002
48. The compound according to claim 47, wherein Ri
IS
Figure imgf000126_0003
49. The compound according to claim 48, wherein Rx is cyclohexyl .
50. A pharmaceutical composition comprising a compound according to any one of claims 1-49 or a pharmaceutically acceptable salt thereof in an amount effective to inhibit a serine protease; and a acceptable carrier, adjuvant or vehicle.
51. The composition according to claim 50, wherein said composition is formulated for administration to a patient.
52. The composition according to claim 51, wherein said composition comprises an additional agent selected from an immunomodulatory agent; an antiviral agent; a second inhibitor of HCV protease; an inhibitor of another target in the HCV life cycle; and a cytochrome P-450 inhibitor; or combinations thereof.
53. The composition according to claim 50, wherein said immunomodulatory agent is α-, β-, or γ-interferon or thymosin; said antiviral agent is ribavirin, amantadine, or telbivudine; or said inhibitor of another target in the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.
54. The composition according to claim 52, wherein said cytochrome P-450 inhibitor is ritonavir.
55. A method of inhibiting the activity of a serine protease comprising the step of contacting said serine protease with a compound according to any one of claims 1-49.
56. The method according to claim 55, wherein said serine protease is an HCV NS3 protease.
57. A method of treating an HCV infection in a patient comprising the step of administering to said patient a composition according to claim 51.
58. The method according to claim 57, comprising the additional step of administering to said patient an additional agent selected from an immunomodulatory agent; an antiviral agent; a second inhibitor of HCV protease; an inhibitor of another target in the HCV life cycle; or combinations thereof; wherein said additional agent is administered to said patient as part of said composition according to claim 51 or as a separate dosage form.
59. The method according to claim 58, wherein said immunomodulatory agent is —, β-, or γ-interferon or thymosin; said antiviral agent is ribavarin or amantadine; or said inhibitor of another target in the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.
60. A method of eliminating or reducing HCV contamination of a biological sample or medical or laboratory equipment, comprising the step of contacting said biological sample or medical or laboratory equipment with a composition according to claim 50.
61. The method according to claim 60, wherein said sample or equipment is selected from blood, other body fluids, biological tissue, a surgical instrument, a surgical garment, a laboratory instrument, a laboratory garment, a blood or other body fluid collection apparatus; a blood or other body fluid storage material.
62. The method according to claim 61, wherein said body fluid is blood.
63. A process for preparing a compound of formula I, as defined in any one of claims 1-49, comprising the step of: reacting a compound of formula VII in the presence of a compound of formula VIII to provide a compound of formula IX:
Figure imgf000129_0001
VII VIII IX wherein: i
R2ι is an amine protecting group, a P3- residue of an HCV protease inhibitor described herein, or a P4-P3- residue of an HCV protease inhibitor as described herein, and wherein the P3 and the P4-P3 residues are optionally protected with an amino-terminal capping group; R0 is a carboxy protecting group or a Pi residue of an HCV protease inhibitor described herein, wherein the Pi residue is optionally protected with a carboxy terminal protecting group or with W; R' is as defined in claim 1; and X is an appropriate leaving group.
PCT/US2004/011011 2003-04-11 2004-04-09 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease WO2004092161A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04759361A EP1613620A1 (en) 2003-04-11 2004-04-09 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/412,600 US7273885B2 (en) 2002-04-11 2003-04-11 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US10/412,600 2003-04-11
US51031703P 2003-10-10 2003-10-10
US60/510,317 2003-10-10

Publications (1)

Publication Number Publication Date
WO2004092161A1 true WO2004092161A1 (en) 2004-10-28

Family

ID=42778107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011011 WO2004092161A1 (en) 2003-04-11 2004-04-09 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Country Status (5)

Country Link
US (2) US7365092B2 (en)
EP (1) EP1613620A1 (en)
AR (1) AR043859A1 (en)
TW (1) TW200510391A (en)
WO (1) WO2004092161A1 (en)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007681A3 (en) * 2003-07-18 2005-06-02 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005035525A3 (en) * 2003-09-05 2005-10-20 Vertex Pharma 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005037860A3 (en) * 2003-10-10 2005-11-10 Vertex Pharmaceuticals Incopor Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2006100106A1 (en) * 2005-03-21 2006-09-28 Smithkline Beecham Corporation 3-carboxy pyrroles as anti-viral agents
WO2006119646A1 (en) 2005-05-13 2006-11-16 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US7368452B2 (en) 2003-04-18 2008-05-06 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US7608590B2 (en) 2004-01-30 2009-10-27 Medivir Ab HCV NS-3 serine protease inhibitors
WO2010138791A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
WO2011066241A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
WO2011068715A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
WO2011079327A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
EP2364984A1 (en) 2005-08-26 2011-09-14 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
WO2011112429A1 (en) 2010-03-09 2011-09-15 Schering Corporation Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2011119860A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119870A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119853A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006055A2 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
US8148399B2 (en) 2005-07-29 2012-04-03 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8314141B2 (en) 1996-10-18 2012-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
WO2013016490A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
EP2559691A1 (en) 2006-11-15 2013-02-20 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of Flavivirus infections
US8389560B2 (en) 2009-09-15 2013-03-05 Taigen Biotechnology Co., Ltd. HCV protease inhibitors
WO2013034048A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033971A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013034047A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substitued benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US8426359B2 (en) 2003-09-18 2013-04-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
US11267803B2 (en) 2016-06-21 2022-03-08 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11377439B2 (en) 2016-06-21 2022-07-05 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001251165A1 (en) * 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
NZ561851A (en) * 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8397205B2 (en) * 2003-08-07 2013-03-12 National Instruments Corporation Graphically representing timing in a graphical program
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
KR20060120162A (en) * 2003-10-27 2006-11-24 버텍스 파마슈티칼스 인코포레이티드 Combinations for hcv treatment
JP4942485B2 (en) * 2003-10-28 2012-05-30 バーテックス ファーマシューティカルズ インコーポレイテッド Preparation of 4,5-dialkyl-3-acyl-pyrrole-2-carboxylic acid derivatives by FISCHER-FINK synthesis and subsequent acylation
AU2005212257A1 (en) * 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP5249028B2 (en) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Novel macrocyclic inhibitor of hepatitis C virus replication
AU2006275413B2 (en) 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2357170A1 (en) 2005-08-19 2011-08-17 Vertex Pharmaceuticals Incorporated Processes and intermediates
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
DE602006019323D1 (en) * 2005-10-11 2011-02-10 Intermune Inc COMPOUNDS AND METHOD FOR INHIBITING THE REPLICATION OF THE HEPATITIS C VIRUS
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1951748B1 (en) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
JP5436864B2 (en) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Co-crystal containing VX-950 and pharmaceutical composition containing the same
EP1993994A2 (en) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
ES2379905T3 (en) * 2007-02-27 2012-05-04 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising them
NZ579295A (en) * 2007-02-27 2012-03-30 Vertex Pharma Inhibitors of serine proteases
EP2177523A1 (en) * 2007-05-03 2010-04-21 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CN102872461A (en) 2007-05-04 2013-01-16 弗特克斯药品有限公司 Combination therapy for the treatment of hcv infection
JP2010526834A (en) * 2007-05-10 2010-08-05 インターミューン・インコーポレーテッド Novel peptide inhibitors of hepatitis C virus replication
CL2008002549A1 (en) 2007-08-30 2010-09-03 Vertex Pharma Cocrystal comprising vx-950 and a cocrystal former selected from 3-methoxy-4-hydroxybenzoic acid, 2,4-dihydroxybenzoic acid and 2,5-dihydroxybenzoic acid; Preparation method; Pharmaceutical composition comprising cocrystal, useful as an antiviral agent in the treatment of hcv.
SG175692A1 (en) * 2008-04-15 2011-11-28 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
EA201170441A1 (en) * 2008-10-15 2012-05-30 Интермьюн, Инк. THERAPEUTIC ANTI-VIRAL PEPTIDES
AR075584A1 (en) * 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND.
CA2775697A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017679A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2003006490A1 (en) * 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
WO2003087092A2 (en) * 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281170T3 (en) 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated SERINA PROTEASES INHIBITORS, PARTICULARLY PROTEASE NS3 OF THE HEPATITIS VIRUS C.
AU2001251165A1 (en) 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
NZ531681A (en) 2001-10-24 2007-05-31 Vertex Pharma Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
CA2521678A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1646642A2 (en) 2003-07-18 2006-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1664091A1 (en) 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2541634A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AU2005212257A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017679A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2003006490A1 (en) * 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
WO2003087092A2 (en) * 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease

Cited By (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314141B2 (en) 1996-10-18 2012-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US7368452B2 (en) 2003-04-18 2008-05-06 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US7109172B2 (en) 2003-07-18 2006-09-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005007681A3 (en) * 2003-07-18 2005-06-02 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US8691758B2 (en) 2003-07-18 2014-04-08 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP2008500265A (en) * 2003-07-18 2008-01-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド Inhibitors of serine proteases, in particular HCV NS3-NS4A protease
EP2368900A3 (en) * 2003-07-18 2012-07-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP2341065A3 (en) * 2003-07-18 2012-06-20 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4a protease
AU2010257200B2 (en) * 2003-07-18 2011-10-20 Vertex Pharmaceuticals Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
JP4745230B2 (en) * 2003-07-18 2011-08-10 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of serine proteases, in particular HCV NS3-NS4A protease
AU2004279800B2 (en) * 2003-09-05 2011-06-30 Vertex Pharmaceuticals Incorporated 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP2573083A1 (en) * 2003-09-05 2013-03-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005035525A3 (en) * 2003-09-05 2005-10-20 Vertex Pharma 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7378422B2 (en) 2003-09-05 2008-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2004279800B9 (en) * 2003-09-05 2011-08-25 Vertex Pharmaceuticals Incorporated 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8426359B2 (en) 2003-09-18 2013-04-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8039623B2 (en) 2003-10-10 2011-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005037860A3 (en) * 2003-10-10 2005-11-10 Vertex Pharmaceuticals Incopor Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP2361925A1 (en) * 2003-10-10 2011-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7208600B2 (en) 2003-10-10 2007-04-24 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases
US7608590B2 (en) 2004-01-30 2009-10-27 Medivir Ab HCV NS-3 serine protease inhibitors
US7671032B2 (en) 2004-01-30 2010-03-02 Medivir Ab HCV NS-3 serine protease inhibitors
US10172846B2 (en) 2004-01-30 2019-01-08 Medivir Ab HCV NS-3 serine protease inhibitors
WO2006100106A1 (en) * 2005-03-21 2006-09-28 Smithkline Beecham Corporation 3-carboxy pyrroles as anti-viral agents
WO2006119646A1 (en) 2005-05-13 2006-11-16 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
EP2546246A2 (en) 2005-05-13 2013-01-16 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
EP2543664A1 (en) 2005-05-13 2013-01-09 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US8741926B2 (en) 2005-07-29 2014-06-03 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis C virus
US8148399B2 (en) 2005-07-29 2012-04-03 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
US9040562B2 (en) 2005-07-29 2015-05-26 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis C virus
US8153800B2 (en) 2005-07-29 2012-04-10 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
US8754106B2 (en) 2005-07-29 2014-06-17 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis C virus
US8349869B2 (en) 2005-07-29 2013-01-08 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis C virus
US9353103B2 (en) 2005-07-29 2016-05-31 Janssen Sciences Ireland Uc Macrocyclic inhibitors of hepatitis C virus
US9856265B2 (en) 2005-07-29 2018-01-02 Janssen Sciences Ireland Uc Macrocyclic inhibitors of hepatitis C virus
US9623022B2 (en) 2005-07-29 2017-04-18 Janssen Sciences Ireland Uc Macrocyclic inhibitors of hepatitis C virus
EP2366704A1 (en) 2005-08-26 2011-09-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2364984A1 (en) 2005-08-26 2011-09-14 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2559692A1 (en) 2006-11-15 2013-02-20 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of Flavivirus infections
EP2559691A1 (en) 2006-11-15 2013-02-20 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of Flavivirus infections
WO2010138791A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8389560B2 (en) 2009-09-15 2013-03-05 Taigen Biotechnology Co., Ltd. HCV protease inhibitors
WO2011068715A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
WO2011066241A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011079327A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011112429A1 (en) 2010-03-09 2011-09-15 Schering Corporation Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119860A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119870A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119853A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006055A2 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013016492A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016501A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Formulations of thiophene compounds
WO2013016490A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016491A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
US9265773B2 (en) 2011-09-08 2016-02-23 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013034048A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013034047A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substitued benzofuran derivatives and methods of use thereof for the treatment of viral diseases
US9549917B2 (en) 2011-09-08 2017-01-24 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
US9573939B2 (en) 2011-09-08 2017-02-21 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033971A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US11267803B2 (en) 2016-06-21 2022-03-08 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11377439B2 (en) 2016-06-21 2022-07-05 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
US11866422B2 (en) 2016-06-21 2024-01-09 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives

Also Published As

Publication number Publication date
US7365092B2 (en) 2008-04-29
AR043859A1 (en) 2005-08-17
US20050080017A1 (en) 2005-04-14
US7906550B2 (en) 2011-03-15
TW200510391A (en) 2005-03-16
EP1613620A1 (en) 2006-01-11
US20080125376A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
US7906550B2 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
RU2412198C2 (en) Inhibitors of serine proteases, in particular, hc-3-hc4a protease
EP1636208B1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP4767852B2 (en) Inhibitors of serine proteases, especially HCV NS3-NS4A
JP4685775B2 (en) Inhibitors of serine proteases, especially HCV NS3-NS4A protease
US20040018986A1 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005007681A9 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP2007532474A (en) Inhibitors of serine proteases, especially NS3-NS4A protease of HCV
AU2011203054B2 (en) Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
MXPA06000686A (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004759361

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004759361

Country of ref document: EP